

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000736 A1

- (51) International Patent Classification⁷: C07K 16/00, 16/18, 16/46, A61K 39/395, A61P 7/00, 7/02
- (21) International Application Number: PCT/AU02/00827
- (22) International Filing Date: 26 June 2002 (26.06.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/301,154 26 June 2001 (26.06.2001) US
60/300,947 27 June 2001 (27.06.2001) US
- (71) Applicant (for all designated States except US): **AGEN BIOMEDICAL LIMITED** [AU/AU]; 11 Durbell Street, Acacia Ridge, Queensland 4110 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CARR, Francis, J.** [GB/GB]; Birchlea, The Holdings, Balmedie, Aberdeen, Aberdeenshire AB22 8GU (GB). **HAMILTON, Anita, A.** [GB/GB]; 130 Kings Gate, Aberdeen, Aberdeenshire AB15 4EQ (GB).
- (74) Agents: **HUGHES, E., John, L.** et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/000736 A1

(54) Title: HUMANIZED ANTIBODIES DERIVED FROM DD-3B6/22, SPECIFIC FOR THE D-DIMER FRAGMENT OF FIBRIN

(57) Abstract: The present invention is directed to humanised forms of the mouse monoclonal antibody DD-3B6/22. This antibody is specific for D-dimer, a degradation fragment of crosslinked fibrin polymers. The invention also includes the use of these antibodies to detect blood clots *in vivo*.

Humanized antibodies derived from DD-3B6/22, specific for the D-dimer fragment of fibrin

FIELD OF THE INVENTION

5 The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic
10 applications.

BACKGROUND OF THE INVENTION

Bibliographic details of the publications referred to in this specification are collected at the
15 end of the description.

Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.
20

Fibrinogen is a large protein molecule which normally circulates in blood plasma in a dissolved state. In the presence of thrombin, fibrinogen molecules form long thread-like polymers or networks called fibrin which is the primary ingredient of blood clots.

25 Upon digestion with plasmin, fibrinogen forms fragments designated A-E. Fragments D and E are the predominant fragments and there is about twice as much D as there is of E. Fibrinogen has a trinodular shape where fragment E is a central component and fragment D is a terminal component.

30 Plasmin digests of fibrin and fibrinogen can be differentiated from each other using polyacrylamide gel electrophoresis (PAGE). Cross-linking of fibrin with Factor XIIIa

- 2 -

forms dimers of fragment D called D-dimer. Factor XIIIa is an enzyme which introduces covalent bonds between adjacent monomers in fibrin (Budzynski *et al.*, *Blood* 54(4): 794-804, 1979). Factor XIIIa is activated by the thrombin-catalyzed removal of a peptide from a precursor in plasma and in blood platelets. D-dimer is a molecule of about 189,000
5 daltons which consists essentially of two fragment D moieties derived from different fibrin molecules covalently bound by cross-link bonds between the γ chain remnants of fibrinogen. Fibrinogen itself comprises six chains with two copies of an α , β and γ chain.

Another complex (DD)E is formed by plasmin degradation of cross-linked human fibrin
10 and comprises a combination of two D fragments and fragment E.

Other cross-linked derivatives are described by Graeff and Halfer (Graeff and Halfer, "Detection and Relevance of Cross-linked Fibrin Derivatives in Blood", *Seminars in Thrombosis and Hemostasis* 8(1), 1982) and include high molecular weight cross-linked
15 derivatives such as DY, YY, XD, XY, DXD and YXD.

Normal haemostasis or coagulation of blood involves maintaining intravascular constituents in a liquid phase or suspension while concomitantly permitting local deposition of solid phase blood components in areas of vessel damage. In health, it has
20 been assumed, but never experimentally demonstrated, that a balance exists between a low-grade intravascular deposition of fibrin and its removal by fibrinolysis or cellular phagocytosis.

Early clinical observations revealed that some severely ill patients developed signs of
25 haemorrhage and massive bruising and had prolonged clotting times and thrombocytopenia. At postmortem, in some cases, fibrin thrombi were demonstrated in the microvasculature. The diffuse nature of these thrombi gave rise to disseminated intravascular coagulation (DIC) also known as consumptive coagulopathy. Subsequently, the thrombin were associated with conditions such as deep vein thrombosis (DVT) and
30 pulmonary embolism (PE).

- 3 -

Conditions such as DIC, DVT and PE involve activation of the coagulation system resulting in platelet consumption, thrombin generation, fibrin deposition and secondary fibrinolysis. The net biologic effect of this process reflects a balance between fibrin deposition and fibrin clearance. The resulting clinical manifestations may be haemorrhage, when depletion of coagulation factors predominates, or ischemic tissue damage, due to the effects of vascular occlusion amongst other conditions.

DIC, DVT and PE have been reported as a secondary phenomenon in a wide variety of disorders, particularly those accompanied by a combination of shock, acidosis and hypoxemia. The well-recognized clinical associations are sepsis, major trauma, malignancy and obstetric disorders. Recently, DVT has been recognized as a particular problem during prolonged air travel or other prolonged immobility. In any event, activation of the coagulation sequence results in consumption of coagulation protein and platelets, leading to fibrin deposition in the micro-circulation.

15

Ideally, a definitive diagnosis of conditions such as DIC, DVT and PE requires the direct demonstration of diffuse fibrin deposition. The practical difficulty of obtaining multiple direct biopsy evidence to differentiate between localized and generalized fibrin formation has led to the development of indirect tests that are substituted as diagnostic end points. However, these tests are not specific for the syndrome of intravascular fibrin deposition. Their specificity is further reduced by the action of other enzymes that although not able to convert fibrinogen to fibrin can cause similar alterations to thrombin on the other coagulation factors involved in thrombosis. All of the indirect tests are based on the principle that thrombin is the only enzyme (snake venoms excluded) capable of converting fibrinogen to fibrin in mammals.

20
25

Also, apart from the paracoagulation tests that detect the presence of circulating soluble fibrin monomer complexes, none of the more specific thrombin specific tests is readily available or useful for immediate clinical application in the diagnosis of these fibrin-associated conditions. These tests include the FPA (fibrinopeptide A) test where FPA is measured by a specific RIA procedure, fibrin monomer assays, fibrinogen gel exclusion

30

- 4 -

chromatography and tests for FPB (fibrinopeptide B) or thrombin increasable FPB.

Tests with biochemical non-specificity for thrombin action include the prothrombin time (PT), thromboplastin time (A PTT) and thrombin clotting time (TCT) tests. Although
5 frequently useful in practice, it must be recognized that information obtained from these tests is non-specific in nature, acting as a measure of clotting factor depletion regardless of etiology.

Coagulation factor assays have also been found to be relatively non-specific and these
10 include assays for cofactors V and VIII as well as tests for fibrinogen levels.

Tests for fibrin-fibrinogen degradation products so far have not proved to be specific for the action of plasmin on fibrin and may yield positive results where there has been fibrinogenolysis without prior thrombin action on the fibrinogen molecule. These tests
15 include tests for fragments D and E.

Tests for thrombin-mediated platelet interaction or release have been found to be non-specific in nature. These include platelet count, platelet survival and tests of platelet release.
20

The use of radio labeled fibrinogen in relation to identifying clotting factors have also been attempted but found to be time consuming and difficult to perform.

Thus, the efficacy of a diagnostic test lies in its ability to indicate the presence or absence
25 of disease. There are well recognized essential design principles for studies determining the efficacy of a diagnostic test which enables the four indices of sensitivity, specificity, positive predictive value and negative predictive value to be determined. The first requirement is the adoption of a suitable standard for diagnosis. Ideally, this standard should be slightly more than a clinical definition and should be as specific as possible for
30 the disease entity. An inherent difficulty in relation to DVT and PE in particular is that many of the routinely available laboratory tests also lack diagnostic specificity. A low

- 5 -

platelet count supports the likelihood of these conditions but may occur as an isolated finding secondary to infection. Similar limitations apply to many of the coagulation assays. Hypofibrinogenemia does not distinguish between primary fibrinolysis, due either to the action of plasmin or elastases and secondary fibrinolysis following the thrombin-mediated
5 conversion of fibrinogen to fibrin. Alternatively, sensitive tests of thrombin action are available but there are obvious drawbacks with their clinical use. An example is the FPA assay which, although specific for thrombin action, is exquisitely sensitive and may detect localized intravascular coagulation yielding a positive result in uncomplicated venous thrombosis. The clinical significance of an elevated FPA level, even with a positive
10 paracoagulation test, is then at issue, particularly if the platelet count, global clotting tests and fibrinogen level are normal.

For these reasons, sensitivity, specificity and predictive values cannot be determined in a standard fashion. The clinical presentation of these disorders is complex and unpredictable.
15 The application of the available tests for diagnosis are, therefore, best considered in relation to the different clinical syndromes of intravascular coagulation.

Murine monoclonal antibody 3B6 was disclosed (U.S. Patent No. 4,758,524). This antibody is specific for D-dimer and represents the first clot-specific antibody. The ability
20 to use this antibody, however, in humans as a systemic diagnostic agent is limited due to the immunogenicity of the molecule. There is a need, therefore, to modify the 3B6 antibody to reduce its immunogenicity in non-murine animals and humans.

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the
5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one
10 element or more than one element.

In work leading up to the present invention, deimmunization technology was used to reduce the immunogenicity of the 3B6 antibody. This has enabled the development of a thrombosis imaging diagnostic procedure for use in humans. Furthermore, the
15 deimmunized form of the 3B6 antibody permits its use as a clot targeting agent to deliver clot dissolution or clot growth prevention agents such as anti-coagulants to the site of a clot. The deimmunized molecules of the present invention act, therefore, as carriers of diagnostic and therapeutic agents to a target site such as a clot. The molecules may also have their own diagnostic or therapeutic properties. The development of a deimmunized
20 form of the 3B6 antibody has application for a range of conditions such as DVT and PE. Furthermore, the deimmunized 3B6 antibodies can be used in combination with computer assisted tomographic nuclear medicine or planar imaging techniques such as CT, MRI or ultrasound.

25 The present invention provides, therefore, a carrier molecule generally in the form of an immunointeractive molecule and in particular a monoclonal antibody rendered chimeric and/or mutated relative to a parent molecule such that it exhibits reduced capacity for immunogenicity in a target host, such as a human. The process of chimerism or mutation is referred to herein as deimmunization. In a particularly preferred embodiment, the
30 immunointeractive molecule such as the monoclonal antibody is humanized to reduce its immunogenicity in humans. Deimmunization may be conducted in different ways but in a

- 7 -

preferred embodiment, one or more amino acids in the variable (v) region of a monoclonal antibody are mutated (e.g. substituted) to reduce MHC II recognition of peptides derived from this region. In other words, the deimmunization process is aimed at reducing a T cell epitope-mediated immune response to the antibody. The most preferred antibody of the present invention is a deimmunized form of murine monoclonal antibody 3B6 which exhibits specificity for D-dimer. The generation of a deimmunized form of 3B6 permits development *inter alia* of a systemic clot targeting agent for blood clots in humans. This permits its use as an imaging agent and as a vehicle to deliver clot dissolution or clot growth prevention agents such as to the site of a clot.

10

The deimmunized antibody acts, therefore, alone or as a carrier for a range of diagnostic and/or therapeutic agents.

Accordingly, one aspect of the present invention provides a variant of an immunointeractive molecule comprising a portion having specificity for cross-linked fibrin derivatives and which portion is derived from an immunointeractive molecule obtainable from one animal or avian creature wherein the variant exhibits reduced immunogenicity in another animal or avian creature from the same or different species.

20 Preferably, the immunointeractive molecule is a variant monoclonal antibody comprising a portion having specificity for cross-linked fibrin derivatives.

More preferably, the monoclonal antibody is a variant of a murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein the variant murine-derived monoclonal antibody is substantially non-immunogenic in a human.

Preferably, the antibody is a deimmunized antibody molecule having specificity for an epitope recognized by monoclonal antibody 3B6 and comprises at least one of the complementary determining regions (CDRs) of the variable domain derived from the 3B6

30

- 8 -

monoclonal antibody and the remaining immunoglobulin-derived parts of the deimmunized antibody molecule are derived from an immunoglobulin or an analogue thereof from the host for which the antibody is to be deimmunized.

- 5 The present invention provides, therefore, a deimmunized antibody molecule having specificity for an epitope recognized by monoclonal antibody 3B6 wherein at least one of the complementary determining regions (CDRs) of the variable domain of said deimmunized antibody is derived from the the 3B6 monoclonal antibody wherein one or more amino acids in a variable region of said 3B6 antibody is mutated to reduce MHC
10 class II recognition of peptides derived from this region.

The present invention further provides a variant of murine monoclonal antibody 3B6 deimmunized for use in humans comprising one or more amino acid mutations in the v-region of the 3B6 antibody designed to eliminate or reduce peptide fragments of the v-
15 region associating with MHC class II molecule.

The deimmunized immunointeractive molecules are useful alone or as carriers of diagnostic and/or therapeutic agents to a target site such as a blood clot.

- 20 Accordingly, the present invention contemplates a method for detecting a blood clot in a human patient by introducing into the patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting the patient to reporter molecule-detection means to identify the location of the
25 antibody in a clot.

In an alternative embodiment, the deimmunized form of 3B6 is not labeled but a second antibody having anti-immunoglobulin specificity is labeled. This antibody forms a labeled complex with the first mentioned antibody.

30

As a carrier, the deimmunized carrier may deliver any clot binding molecule to the site of a

- 9 -

clot as well as other diagnostic or therapeutic agents.

The present invention contemplates, therefore, the use of a deimmunized murine monoclonal antibody specific for D-dimer or other cross-linked fibrin derivatives in the
5 manufacture of clot imaging agent.

Yet another aspect of the present invention contemplates a method for facilitating the dissolution or removal of a blood clot in a human, said method comprising administering to said human a clot dissolution or clot growth prevention-effective amount of a variant
10 murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant murine-derived monoclonal antibody is substantially non-immunogenic in a human wherein said monoclonal antibody further comprises a clot dissolution or clot growth prevention agent
15 fused, bound or otherwise associated thereto.

Still another aspect of the present invention is directed to the use of a variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation
20 products inclusive of fragments D and E wherein said variant murine-derived monoclonal antibody is substantially non-immunogenic in a human and said antibody further comprising a clot dissolution or clot growth prevention agent fused, bound or otherwise attached thereto in the manufacture of a medicament for the dissolution of a blot clot in a human.

25

A preferred molecule is a variant murine monoclonal antibody 3B6 deimmunized for use in humans and comprising a combination of heavy and light chain v-regions comprising the amino acid sequences encoded by nucleotide sequences selected from SEQ ID NO:7/SEQ ID NO:10, SEQ ID NO:8/SEQ ID NO:10, SEQ ID NO:9/SEQ ID NO:10, SEQ
30 ID NO:7/SEQ ID NO:12, SEQ ID NO:8/SEQ ID NO:12, SEQ ID NO:8/SEQ ID NO:11, SEQ ID NO:9/SEQ ID NO:11, SEQ ID NO:9/SEQ ID NO:12 and SEQ ID NO:7/SEQ ID

- 10 -

NO:11 or combinations of amino acid sequences encoded by nucleotide sequences having at least 70% similarity to one or both amino acid sequences in each of the above listed pairs or nucleotide sequences capable of hybridizing to low stringency conditions to one or both nucleotide sequences or their complementary forms in each of the above listed pairs.

5

The variant 3B6 antibody deimmunized for use preferably comprises a combination of heavy and light chain v-regions comprising the amino acid sequences selected from SEQ ID NO:1/SEQ ID NO:4, SEQ ID NO:2/SEQ ID NO:4, SEQ ID NO:3/SEQ ID NO:4, SEQ ID NO:1/SEQ ID NO:6, SEQ ID NO:2/SEQ ID NO:6, SEQ ID NO:2/SEQ ID NO:5, SEQ ID NO:3/SEQ ID NO:5, SEQ ID NO:3/SEQ ID NO:6 and SEQ ID NO:1/SEQ ID NO:5 or combinations of amino acid sequences having at least 70% similarity to one or both amino acid sequences in each of the above listed pairs.

Another preferred variant of 3B6 comprises a combination of heavy and light chain v-regions selected from VHv5/VKv1, VHv6/VKv1, VHv7/VKv1, VHv5/VKv7, VHv6/VKv7, VHv6/VKv4, VHv7/VKv4, VHv7/VKv7 and VHv5/VKv4.

Another aspect of the present invention contemplates a method for detecting a blood clot in a human patient by introducing into the patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting the patient to a computer assisted tomographic nuclear medicine scan to visualize the clot.

Yet another aspect of the present invention contemplates a method for detecting a blood clot in a human patient by introducing into the patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting said patient to planar clot imaging to visualize the clot.

30

The deimmunized immunointeractive molecule of the present invention is also useful to

- 11 -

anchor an anti-coagulant at a particular site. This aspect provides, therefore, tissue-specific anchoring of a diagnostic or therapeutic agent to, for example, a clot. Furthermore, the immunointeractive molecule may be engineered to have multiple specificities. For example, a bi-specific deimmunized antibody is contemplated which comprises one
5 specificity for a clot and another specificity to a site of a clot (e.g. to a cell receptor). This enables the antibody to remain at the site of the clot.

In an alternative, a multi-step treatment is contemplated where, for example, the deimmunized 3B6 or other interactive molecule conjugated to an anti-coagulant is
10 administered to target the clot and forms a complex and then a second antibody directed to the first antibody and/or the anti-coagulant is administered to enhance or monitor the first complex.

The deimmunized immunointeractive molecule may also be used to determine the kinetics
15 of clot dissipation or clot disappearance. This is useful to predict even earlier the appearance or disappearance of clots and, hence, aids in determining the kinetics of when to initiate second treatments such as anti-coagulant treatments.

The present invention further provides conjugates comprising the deimmunized
20 immunointeractive molecules and imaging and/or therapeutic tags. Examples of imaging tags include MRI, ultrasound and CT tags. Examples of therapeutic tags include radioactive isotopes, anti-clotting agents and cytokines.

A summary of sequence identifiers used throughout the subject specification is provided in Table 1.

TABLE 1 Summary of Sequence Identifiers

5

SEQUENCE ID NO:	DESCRIPTION
1	Amino acid of 3B6DIVHv5
2	Amino acid of 3B6DIVHv6
3	Amino acid of 3B6DIVHv7
4	Amino acid of 3B6DIVKv1
5	Amino acid of 3B6DIVKv4
6	Amino acid 3B6DIVKv7
7	Nucleotide sequence encoding 3B6DIVHv5
8	Nucleotide sequence encoding 3B6DIVHv6
9	Nucleotide sequence encoding 3B6DIVHv7
10	Nucleotide sequence encoding 3B6DIVKv1
11	Nucleotide sequence encoding 3B6DIVKv4
12	Nucleotide sequence encoding 3B6DIVKv7

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a representation showing (A) a schematic of the 3B6 monoclonal antibody; (B) a photograph of 3B6 binding to blood clots (x4,2000 magnification).

5

Figure 2 is a schematic representation of a 3B6 antibody labeled with a nuclear tag (^{99m}Tc).

Figure 3A is a diagrammatic representation showing administration of 3B6 ^{99m}Tc to the
10 circulatory system of a human.

Figure 3B is a photographic representation showing visualization of blood clots in the anterior thighs as radiation from ^{99m}Tc concentrates at the clot site.

15 **Figures 4A, 4B and 4C** are graphical representations showing D-dimer capture assay using deimmunized 3B6 monoclonal antibodies.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the application of biochemical techniques to render an immunointeractive molecule derived from one animal or avian creature substantially non-immunogenic in another animal or avian creature of the same or different species. The biochemical process is referred to herein as “deimmunization”. Reference herein to “deimmunization” includes processes such as complementary determinant region (CDR) grafting, “reshaping” with respect to a framework region of an immunointeractive molecule and variable (v) region mutation, all aimed at reducing the immunogenicity of an immunointeractive molecule in a particular host. In the present case, the preferred immunointeractive molecule is an antibody such as a polyclonal or monoclonal antibody. In a most preferred embodiment, the immunointeractive molecule is a monoclonal antibody, derived from one animal or avian creature and which exhibits reduced immunogenicity in another animal or avian creature from the same or different species.

15

The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. The carrier molecules may exhibit useful diagnostic or therapeutic properties *per se* or may be used to deliver active compounds (e.g. anti-clotting agents, radioactive isotopes) to a target site. Generally, the carrier molecules are immunointeractive molecules. More particularly, the present invention is directed to a deimmunized including a non-murine mammalianized form of a murine-derived monoclonal antibody substantially incapable of inducing an immune response against itself in a non-murine animal and in particular a human. Even more particularly, the present invention provides a deimmunized form of murine monoclonal antibody 3B6 such that it is incapable of, or exhibits reduced capacity for, inducing a substantial immune response against itself or its derivatives when administered to a human. The deimmunized immunointeractive molecules and in particular antibodies of the present invention have a range of useful diagnostic and therapeutic applications such as in the detection of blood clots in the circulatory system of a human and as a clot targeting agent to deliver a clot dissolution or clot growth prevention agent such as an anticoagulant.

30

- 15 -

The demmunized including humanized forms of the subject monoclonal antibody are particularly useful in the diagnosis and treatment of conditions such as deep vein thrombosis and pulmonary embolism. The molecules of the present invention are particularly useful as agents for delivering active compounds to a target site. Such active
5 compounds include clot binding molecules.

Accordingly, one aspect of the present invention provides a variant of an immunointeractive molecule, said variant comprising a portion having specificity for cross-linked fibrin derivatives and which portion is derived from an immunointeractive
10 molecule obtainable from one animal or avian creature wherein said variant exhibits reduced immunogenicity in another animal or avian creature from the same or different species.

As stated above, the preferred form of immunointeractive molecule is an antibody and in
15 particular a monoclonal antibody.

Accordingly, another aspect of the present invention provides a variant monoclonal antibody comprising a portion having specificity for cross-linked fibrin derivatives and which portion is derived from a monoclonal antibody obtainable from a first animal or
20 avian creature wherein said variant exhibits reduced immunogenicity in a second animal or avian creature from the same or different species.

In a particularly preferred embodiment, a monoclonal antibody is obtained from a murine animal and is deimmunized with respect to another murine animal or a different species of
25 animal such as a human. The murine monoclonal antibody is raised in the murine animal to non-denatured D-dimer which is derived from fibrinogen. The latter molecule is digested by plasmin and generates a range of fragments designated fragments A to E. Cross-linking of fibrin with Factor XIIIa forms dimers of fragment D referred to as "D-dimer". The D-dimer is a molecule of about 189,000 daltons and comprises two fragment D moieties
30 bound by cross-linked bonds between the γ chain remnants of fibrinogen.

- 16 -

Accordingly, another aspect of the present invention is directed to a variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant murine-derived monoclonal antibody
5 is substantially non-immunogenic in a human.

Reference to “substantially non-immunogenic” includes reduced immunogenicity compared to a parent antibody, i.e. an antibody before exposure to deimmunization processes. The term “immunogenicity” includes an ability to provoke, induce or otherwise
10 facilitate a humoral and/or T-cell mediated response in a host animal. Particularly convenient immunogenic criteria include the ability for amino acid sequences derived from a variable (v) region of an antibody to interact with MHC class II molecules thereby stimulating or facilitating a T-cell mediating response including a T-cell-assisted humoral response. The immunointeractive molecule and in particular a monoclonal antibody
15 contemplated by the present invention includes reference to a clot targeting agent.

The preferred murine-derived monoclonal antibody is referred to herein as monoclonal antibody 3B6 which is described in U.S. Patent No. 4,758,524.

20 Accordingly, in a particularly preferred embodiment, the present invention provides a deimmunized form of monoclonal antibody 3B6 wherein said deimmunized 3B6 is substantially non-immunogenic in humans.

Again, “substantially non-immunogenic” in this context means a reduced capacity of the
25 deimmunized 3B6 monoclonal antibody to induce or facilitate an immune response against itself (following initial or subsequent administration) in a human compared to murine monoclonal antibody 3B6, prior to deimmunization.

Although the preferred invention is particularly directed to a deimmunized form of 3B6
30 with respect to humans, the present invention extends to this antibody or another antibody with a similar specificity for D-dimer and/or other cross-linked fibrin derivatives

- 17 -

deimmunized for any other animal or avian species.

Reference herein to other cross-linked fibrin derivatives includes, for example, in addition to D-dimer, derivatives of D-dimer and a complex comprising D and E fragments. The latter includes (DD)E and is formed by plasmin degradation of cross-linked human fibrin and comprises a combination of two D fragments and fragment E. Other cross-linked derivatives include DY, YY, XD, XY, DXD and YXD where the letters represent fragments of fibrinogen formed following degradation by plasmin wherein X and Y are different and are selected from fragments A to C and E. Preferably, the deimmunized antibody of the subject invention is derived from an antibody specific for D-dimer and other cross-linked fibrin derivatives but which does not cross-react with fibrinogen, fibrinogen degradation products inclusive of fragment D and fragment E. Preferably, the antibody-producing clones are selected using solution phase D-dimer molecules rather than immobilized D-dimer although clones selected by either form of D-dimer are contemplated by the present invention.

Preferably, the deimmunized antibody exhibits an affinity for its target antigen which is similar to the affinity exhibited by murine monoclonal antibody 3B6.

By "affinity" in relation to the interaction between an individual antigen binding site on an antigen-binding molecule and its corresponding site on the antigen includes the strength of this interaction.

By "antibody" is meant a protein of the immunoglobulin family that is capable of combining, interacting or otherwise associating with an antigen. An antibody is, therefore, an antigen-binding molecule. An "antibody" is an example of an immunointeractive molecule and includes a polyclonal or monoclonal antibody. The preferred immunointeractive molecules of the present invention are monoclonal antibodies. An antibody includes parts thereof including Fab portions and antigen-binding determinants.

30

The term "antigen" is used herein in its broadest sense to refer to a substance that is

- 18 -

capable of reacting in and/or inducing an immune response. Reference to an “antigen” includes an antigenic determinant or epitope. The antigen in the present context is regarded as the immunointeractive molecule and, more particularly, a monoclonal antibody.

5 Any molecule that has binding affinity for a target antigen is referred to as an “antigen-binding molecule”. It will be understood that this term extends to immunoglobulins (e.g. polyclonal or monoclonal antibodies), immunoglobulin fragments and non-immunoglobulin derived protein frameworks that exhibit antigen-binding activity. The terms “antibody” and “antigen-binding molecules” include deimmunized forms of these
10 molecules.

That part of an antigenic molecule against which a particular immune response is directed is referred to as an “antigenic determinant” or “epitope” and includes a hapten. Typically, in an animal, antigens present several or even many antigenic determinants simultaneously.

15 A “hapten” is a substance that can combine specifically with an antibody but cannot or only poorly induces an immune response unless bound to a carrier. A hapten typically comprises a single antigenic determinant or epitope.

As stated above, although the preferred antibodies of the present invention are
20 deimmunized forms of murine monoclonal antibodies for use in humans, the subject invention extends to antibodies from any source and deimmunized for use in any host. Examples of animal and avian sources and hosts include humans, primates, livestock animals (e.g. sheep, cows, horses, pigs, donkeys), laboratory test animals (e.g. mice, rabbits, guinea pigs, hamsters), companion animals (e.g. dogs, cats), poultry bird (e.g.
25 chickens, ducks, geese, turkeys) and game birds (e.g. pheasants). The deimmunized antibodies or part thereof may also be generated in non-animal tissues such as plants. Plants are particularly useful as a source of single chain antibodies.

Another aspect of the present invention contemplates a method for generating a
30 deimmunized monoclonal antibody having specificity for antigenic determinants on human D-dimer or other cross-linked fibrin derivatives, said method comprising:-

- 19 -

- (i) obtaining a cross-linked fibrin derivative or extract containing same from a human;
- (ii) generating an antibody in a non-human animal specific to said cross-linked fibrin derivative but which does not cross-react with fragment D; and
- (iii) subjecting said non-human derived antibody to deimmunization means.

The cross-linked fibrin derivative may be derived from any suitable antigenic extract including plasmin-mediated degradation of fibrin clots or by simultaneous action of thrombin, Factor XIIIa and plasmin on fibrinogen with transient clot formation and subsequent clot lysis. In the latter method, the fibrinogen is converted to fibrin by the action of thrombin and Factor XIIIa and subsequently digested with plasmin. It will, of course, be appreciated that the fibrin derivative or extract containing same may be obtained from an animal source other than human. The antigenic source is conveniently from a biological sample.

A sample that may be extracted, untreated, treated, diluted or concentrated from an animal is included in the term "biological sample".

The above method of obtaining the crude antigenic fraction represents an *in vitro* method. A suitable *in vivo* method includes obtaining sera or other body fluid containing the cross-linked fibrin derivative from an animal including human and subjecting the body fluid to a PAGE process wherein substantially pure cross-linked fibrin derivative is isolated.

Alternatively, cross-linked fibrin derivatives may be purified from serum obtained from patients suffering severe thrombotic disorders based on a technique using gel filtration in combination with ion exchange chromatography as described by Willner *et al.*, *Biochemistry* 21: 2687-2692, 1982.

- 20 -

The antigen (i.e. D-dimer or other cross-linked fibrin derivative) can be separated from the biological sample by any suitable means. For example, the separation may take advantage of any one or more of the antigen's surface charge properties, size, density, biological activity and its affinity for another entity (e.g. another protein or chemical compound to which it binds or otherwise associates). Thus, for example, separation of the antigen from the biological fluid may be achieved by any one or more of ultra-centrifugation, ion-exchange chromatography (e.g. anion exchange chromatography, cation exchange chromatography), electrophoresis (e.g. polyacrylamide gel electrophoresis, isoelectric focussing), size separation (e.g., gel filtration, ultra-filtration) and affinity-mediated separation (e.g. immunoaffinity separation including, but not limited to, magnetic bead separation such as Dynabead™ separation, immunochromatography, immunoprecipitation). Choice of the separation technique(s) employed may depend on the biological activity or physical properties of the particular antigen.

Preferably, the separation of the antigen from the biological fluid preserves conformational epitopes present on the antigen surface and, thus, suitably avoids techniques that cause denaturation of the antigen. Persons of skill in the art will recognize the importance of maintaining or mimicking as close as possible physiological conditions peculiar to the antigen (e.g. the biological fluid from which they are obtained) to ensure that the antigenic determinants or active site/s on the antigen, which are exposed to the animal, are structurally identical to that of the native antigen. This ensures the raising of appropriate antibodies in the immunised animal that would recognize the native antigen. In a preferred embodiment of this type, the antigen is separated from the biological fluid using any one or more of affinity separation, gel filtration and ultra-filtration.

25

Immunization and subsequent production of monoclonal antibodies can be carried out using standard protocols as for example described by Köhler and Milstein (*Nature* 256: 495-499, 1975; Köhler and Milstein, *Eur. J. Immunol.* 6(7): 511-519, 1976), Coligan *et al.* (*Current Protocols in Immunology*, John Wiley & Sons, Inc., 1991-1997) or Toyama *et al.* (*"Monoclonal Antibody, Experiment Manual"*, published by Kodansha Scientific, 1987). Essentially, an animal is immunized with an antigen-containing biological fluid or fraction

- 21 -

thereof by standard methods to produce antibody-producing cells, particularly antibody-producing somatic cells (e.g. B lymphocytes). These cells can then be removed from the immunized animal for immortalization. The antigen may need to first be associated with a larger molecule. The latter is any substance of typically high molecular weight to which a non- or poorly immunogenic substance (e.g. a hapten) is naturally or artificially linked to enhance its immunogenicity.

Immortalization of antibody-producing cells may be carried out using methods, which are well-known in the art. For example, the immortalization may be achieved by the transformation method using Epstein-Barr virus (EBV) (Kozbor *et al.*, *Methods in Enzymology* 121: 140, 1986). In a preferred embodiment, antibody-producing cells are immortalized using the cell fusion method (described in Coligan *et al.*, 1991-1997, *supra*), which is widely employed for the production of monoclonal antibodies. In this method, somatic antibody-producing cells with the potential to produce antibodies, particularly B cells, are fused with a myeloma cell line. These somatic cells may be derived from the lymph nodes, spleens and peripheral blood of primed animals, preferably rodent animals such as mice and rats. In the exemplary embodiment of this invention mice, spleen cells are used. It would be possible, however, to use rat, rabbit, sheep or goat cells, or cells from other animal species instead.

20

Specialized myeloma cell lines have been developed from lymphocytic tumours for use in hybridoma-producing fusion procedures (Köhler and Milstein, 1976, *supra*; Shulman *et al.*, *Nature* 276: 269-270, 1978; Volk *et al.*, *J. Virol.* 42(1): 220-227, 1982). These cell lines have been developed for at least three reasons. The first is to facilitate the selection of fused hybridomas from unfused and similarly indefinitely self-propagating myeloma cells. Usually, this is accomplished by using myelomas with enzyme deficiencies that render them incapable of growing in certain selective media that support the growth of hybridomas. The second reason arises from the inherent ability of lymphocytic tumour cells to produce their own antibodies. To eliminate the production of tumour cell antibodies by the hybridomas, myeloma cell lines incapable of producing endogenous light or heavy immunoglobulin chains are used. A third reason for selection of these cell lines is

30

for their suitability and efficiency for fusion.

Many myeloma cell lines may be used for the production of fused cell hybrids, including, e.g. P3X63-Ag8, P3X63-AG8.653, P3/NS1-Ag4-1 (NS-1), Sp2/0-Ag14 and
5 S194/5.XXO.Bu.1. The P3X63-Ag8 and NS-1 cell lines have been described by Köhler and Milstein (1976, *supra*). Shulman *et al.* (1978, *supra*) developed the Sp2/0-Ag14 myeloma line. The S194/5.XXO.Bu.1 line was reported by Trowbridge (*J. Exp. Med.* 148(1): 313-323, 1978).

10 Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually involve mixing somatic cells with myeloma cells in a 10:1 proportion (although the proportion may vary from about 20:1 to about 1:1), respectively, in the presence of an agent or agents (chemical, viral or electrical) that promotes the fusion of cell membranes. Fusion methods have been described (Köhler and Milstein, 1975,
15 *supra*; Köhler and Milstein, 1976, *supra*; Gefter *et al.*, *Somatic Cell Genet.* 3: 231-236, 1977; Volk *et al.*, 1982, *supra*). The fusion-promoting agents used by those investigators were Sendai virus and polyethylene glycol (PEG).

Because fusion procedures produce viable hybrids at very low frequency (e.g. when
20 spleens are used as a source of somatic cells, only one hybrid is obtained for roughly every 1×10^5 spleen cells), it is preferable to have a means of selecting the fused cell hybrids from the remaining unfused cells, particularly the unfused myeloma cells. A means of detecting the desired antibody-producing hybridomas among other resulting fused cell hybrids is also necessary. Generally, the selection of fused cell hybrids is accomplished by culturing
25 the cells in media that support the growth of hybridomas but prevent the growth of the unfused myeloma cells, which normally would go on dividing indefinitely. The-somatic cells used in the fusion do not maintain long-term viability in *in vitro* culture and hence do not pose a problem. In the example of the present invention, myeloma cells lacking hypoxanthine phosphoribosyl transferase (HPRT-negative) were used. Selection against
30 these cells is made in hypoxanthine/aminopterin/thymidine (HAT) medium, a medium in which the fused cell hybrids survive due to the HPRT-positive genotype of the spleen cells.

- 23 -

The use of myeloma cells with different genetic deficiencies (drug sensitivities, etc.) that can be selected against in media supporting the growth of genotypically competent hybrids is also possible.

5 Several weeks are required to selectively culture the fused cell hybrids. Early in this time period, it is necessary to identify those hybrids which produce the desired antibody, so that they may subsequently be cloned and propagated. Generally, around 10% of the hybrids obtained produce the desired antibody, although a range of from about 1 to about 30% is not uncommon. The detection of antibody-producing hybrids can be achieved by any one
10 of several standard assay methods, including enzyme-linked immunoassay and radioimmunoassay techniques as, for example, described in Kennet *et al.* ((eds) *Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses*, pp. 376-384, Plenum Press, New York, 1980). In a particularly preferred embodiment, an enzyme linked immunosorbent assay (ELISA) is performed to selected antibody producing
15 clones using solution phase D-dimer.

Once the desired fused cell hybrids have been selected and cloned into individual antibody-producing cell lines, each cell line may be propagated in either of two standard ways. A suspension of the hybridoma cells can be injected into a histocompatible animal.
20 The injected animal will then develop tumours that secrete the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can be tapped to provide monoclonal antibodies in high concentration. Alternatively, the individual cell lines may be propagated *in vitro* in laboratory culture vessels. The culture medium containing high concentrations of a single specific
25 monoclonal antibody can be harvested by decantation, filtration or centrifugation, and subsequently purified.

The cell lines are tested for their specificity to detect the antigen of interest by any suitable immunodetection means. For example, cell lines can be aliquoted into a number of wells
30 and incubated and the supernatant from each well is analyzed by enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody technique, or the like. The

- 24 -

cell line(s) producing a monoclonal antibody capable of recognizing the target antigen but which does not recognize non-target epitopes are identified and then directly cultured *in vitro* or injected into a histocompatible animal to form tumours and to produce, collect and purify the required antibodies.

5

Thus, the present invention provides in a first step monoclonal antibodies which specifically interact with D-dimer or other cross-linked fibrin derivative.

As indicated above, non-animal cells such as a plant, yeast and/or microbial cells may be used to generate typically single-chain antibodies. In this embodiment, such cells are engineered to express nucleic acid molecules which encode a chain of an antibody.

The monoclonal antibody is then subjected to deimmunization means. Such a process may take any of a number of forms including the preparation of chimeric antibodies which have the same or similar specificity as the monoclonal antibodies prepared according to the present invention. Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes belonging to different species. Thus, in accordance with the present invention, once a hybridoma producing the desired monoclonal antibody is obtained, techniques are used to produce interspecific monoclonal antibodies wherein the binding region of one species is combined with a non-binding region of the antibody of another species (Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 84: 3439-3443, 1987). For example, the CDRs from a non-human (e.g. murine) monoclonal antibody can be grafted onto a human antibody, thereby "humanizing" the murine antibody (European Patent Publication No. 0 239 400; Jones *et al.*, *Nature* 321: 522-525, 1986; Verhoeven *et al.*, *Science* 239: 1534-1536, 1988; Riechmann *et al.*, *Nature* 332: 323-327, 1988). In this case, the deimmunizing process is specific for humans. More particularly, the CDRs can be grafted onto a human antibody variable region with or without human constant regions. The non-human antibody providing the CDRs is typically referred to as the "donor" and the human antibody providing the framework is typically referred to as the "acceptor". Constant regions need not be present, but if they are, they must be substantially identical to human

- 25 -

immunoglobulin constant regions, i.e. at least about 85-90%, preferably about 95% or more identical. Hence, all parts of a humanized antibody, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences. Thus, a "humanized antibody" is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. A donor antibody is said to be "humanized", by the process of "humanization", because the resultant humanized antibody is expected to bind to the same antigen as the donor antibody that provides the CDRs. Reference herein to "humanized" includes reference to an antibody deimmunized to a particular host, in this case, a human host.

10

It will be understood that the deimmunized antibodies may have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. Exemplary conservative substitutions may be made according to Table 2.

15

TABLE 2

ORIGINAL RESIDUE	EXEMPLARY SUBSTITUTIONS
Ala	Ser
Arg	Lys
Asn	Gln, His
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Pro
His	Asn, Gln
Ile	Leu, Val
Leu	Ile, Val
Lys	Arg, Gln, Glu

- 26 -

ORIGINAL RESIDUE	EXEMPLARY SUBSTITUTIONS
Met	Leu, Ile
Phe	Met, Leu, Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp, Phe
Val	Ile, Leu

Exemplary methods which may be employed to produce deimmunized antibodies according to the present invention are described, for example, in Richmann *et al.*, 1988, *supra*; U.S. Patent Nos. 6,056,957, 6,180,370 and 6,180,377 and Chothia *et al.*, *J. Mol. Biol.* 196: 901, 1987.

Thus, in one embodiment, the present invention contemplates a deimmunized antibody molecule having specificity for an epitope recognized by monoclonal antibody 3B6 wherein at least one or at least two or at least three or at least four or at least five of the complementary determining regions (CDRs) of the variable domain of said deimmunized antibody is derived from said 3B6 monoclonal antibody and the remaining immunoglobulin-derived parts of the deimmunized antibody molecule are derived from an immunoglobulin or an analogue thereof from the host for which the antibody is to be deimmunized.

This aspect of the present invention involves manipulation of the framework region of a non-human antibody.

Preferably, the deimmunized antibody is a humanized form of murine 3B6.

One preferred deimmunization process is referred to herein a variable(v)-region grafting and results in a chimeric antibody. The resulting antibody comprises one or more amino acid substitutions within the v-region when compared to the present (e.g. murine) antibody.

The rationale for making v-region changes is to further the potential for an induced immune response in the intended host (e.g. a human). The basis of deimmunization is predicated in part on the assumption that a substantive immune response to an introduced antibody requires a T-cell mediated response. The trigger for the T-cell response is the presentation of processed peptides emanating from the introduced antibody on the surface of antigen presenting cells (APCs). The APCs present such peptides in association with surface MHC class II molecules. The deimmunized approach is, therefore, based on:-

- 5 (i) predicting peptide sequences capable of associating with MHC class II molecules;
10 and
- (ii) changing strategic residues to eliminate the ability of the peptide to associate with the MHC class II molecule.

15 Accordingly, another aspect of the present invention provides a variant of murine monoclonal antibody 3B6 deimmunized for use in humans, said variant comprising one or more amino acid mutations in the v-region of said 3B6 antibody to eliminate or reduce peptide fragments of said v-region associating with MHC class II molecules.

20 One or more amino acid substitutions, additions and/or deletions or one or more nucleotide substitutions, additions and/or deletions is encompassed by the term "mutation" or "mutations".

In a particularly preferred embodiment, the deimmunized antibodies are generated by co-
25 transfection of different combinations of three deimmunized H-chain genes and three deimmunized L-chain genes. The resulting variants are derived from different combinations encoded by H-chain and L-chain genes. Preferred H-chains are Hv5, Hv6 and Hv7. These are referred to herein as 3B6DIVHv5 (SEQ ID NO:1), 3B6DIVHv6 (SEQ ID NO:2) and 3B6DIVHv7 (SEQ ID NO:3). Preferred L-chains are Kv1, Kv4 and Kv7.
30 These are referred to herein as 3B6DIVKv1 (SEQ ID NO:4), 3B6DIVKv4 (SEQ ID NO:5) and 3B6DIVKv7 (SEQ ID NO:6). Particularly useful combinations include VHv5/VKv1,

- 28 -

VHv6/VKv1, VHv7/VKv1, VHv5/VKv7, VHv6/VKv7, VHv6/VKv4, VHv7/VKv4,
VHv7/VKv7 and VHv5/VKv4. The sequence identifier numbers (SEQ ID NOS:) in
parentheses represent the amino acid sequences of the particular chains. Corresponding
nucleotide sequences encoding each of SEQ ID NOS:1-6 are represented by SEQ ID
5 NOS:7-12.

All such combinations of H and L chains are also encompassed by the present invention.

Accordingly, the present invention provides a variant murine monoclonal antibody 3B6
10 deimmunized for use in humans, said variant comprising a combination of heavy and light
chain v-regions comprising the amino acid sequences encoded by nucleotide sequences
selected from SEQ ID NO:7/SEQ ID NO:10, SEQ ID NO:8/SEQ ID NO:10, SEQ ID
NO:9/SEQ ID NO:10, SEQ ID NO:7/SEQ ID NO:12, SEQ ID NO:8/SEQ ID NO:12, SEQ
ID NO:8/SEQ ID NO:11, SEQ ID NO:9/SEQ ID NO:11, SEQ ID NO:9/SEQ ID NO:12
15 and SEQ ID NO:7/SEQ ID NO:11 or combinations of amino acid sequences encoded by
nucleotide sequences having at least 70% similarity to one or both amino acid sequences in
each of the above listed pairs or nucleotide sequences capable of hybridizing to low
stringency conditions to one or both nucleotide sequences or their complementary forms in
each of the above listed pairs.

20

All such combinations of H and L chains are also encompassed by the present invention.

Accordingly, the present invention provides a variant murine monoclonal antibody 3B6
deimmunized for use in humans, said variant comprising a combination of heavy and light
25 chain v-regions comprising the amino acid sequences selected from SEQ ID NO:1/SEQ ID
NO:4, SEQ ID NO:2/SEQ ID NO:4, SEQ ID NO:3/SEQ ID NO:4, SEQ ID NO:1/SEQ ID
NO:6, SEQ ID NO:2/SEQ ID NO:6, SEQ ID NO:2/SEQ ID NO:5, SEQ ID NO:3/SEQ ID
NO:5, SEQ ID NO:3/SEQ ID NO:6 and SEQ ID NO:1/SEQ ID NO:5 or combinations of
amino acid sequences encoded by nucleotide sequences having at least 70% similarity to
30 one or both amino acid sequences in each of the above listed pairs.

- 29 -

More particularly, the present invention provides a variant of a murine monoclonal antibody 3B6 deimmunized for use in humans, said variant comprising a combination of heavy and light chain v-regions selected from VHv5/VKv1, VHv6/VKv1, VHv7/VKv1, VHv5/VKv7, VHv6/VKv7, VHv6/VKv4, VHv7/VKv4, VHv7/VKv7 and VHv5/VKv4.

5

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide and sequence comparisons are made at the level of identity rather than similarity.

15

Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence", "comparison window", "sequence similarity", "sequence identity", "percentage of sequence similarity", "percentage of sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window

- 30 -

may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as, for example, disclosed by Altschul *et al.* (*Nucl. Acids Res.* 25: 3389-3402. 1997). A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel *et al.* ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-1998, Chapter 15).

5
10

The terms "sequence similarity" and "sequence identity" as used herein refers to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C, G, I) or the identical amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.

15
20
25

Mutations and derivatives contemplated by the present invention include redundant mutations in nucleotide sequences which do not result in a change in amino acid sequence.

30

- 31 -

Reference herein to a low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may
5 be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing
10 conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out $T_m = 69.3 + 0.41 (G+C)\%$ (Marmur and Doty, *J. Mol. Biol.* 5: 109, 1962). However, the T_m of a duplex DNA decreases by 1°C
15 with every increase of 1% in the number of mismatch base pairs (Bonner and Laskey, *J. Mol. Biol.* 5: 109, 1962). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x
20 SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.

As used herein, the term "CDR" includes CDR structural loops which covers to the three light chain and the three heavy chain regions in the variable portion of an antibody framework region which bridge β strands on the binding portion of the molecule. These
25 loops have characteristic canonical structures (Chothia *et al.*, *J. Mol. Biol.* 227: 799, 1992; Kabat *et al.*, "Sequences of Proteins of Immunological Interest", U.S. Department of Health and Human Services, 1983).

An immunoglobulin light or heavy chain variable region, which is interrupted by three
30 hypervariable regions, also called CDRs, is referred to herein as a "framework region". The extent of the framework region and CDRs have been precisely defined (see, for

- 32 -

example, Krebber *et al.*, *J. Immunol. Methods* 201(1): 35-55, 19). The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. As used herein, a “human framework region” is a framework region that is substantially identical (about 85% or more, usually 90-95% or more) to the framework region of a naturally occurring human immunoglobulin. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs. The CDRs are primarily responsible for binding to an epitope of an antigen.

10 As used herein, the term “heavy chain variable region” means a polypeptide which is from about 110 to 125 amino acid residues in length, the amino acid sequence of which corresponds to that of a heavy chain of a monoclonal antibody of the invention, starting from the amino-terminal (N-terminal) amino acid residue of the heavy chain. Likewise, the term “light chain variable region” means a polypeptide which is from about 95 to 130 amino acid residues in length, the amino acid sequence of which corresponds to that of a light chain of a monoclonal antibody of the invention, starting from the N-terminal amino acid residue of the light chain. Full-length immunoglobulin “light chains” (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH₂-terminus (about 110 amino acids) and a κ or λ constant region gene at the COOH-terminus. Full-length immunoglobulin “heavy chains” (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g. γ (encoding about 330 amino acids).

The term “immunogenicity” is used herein in its broadest sense to include the property of evoking an immune response within an organism. Immunogenicity typically depends partly upon the size of the substance in question, and partly upon how unlike host molecules it is. It is generally considered that highly conserved proteins tend to have rather low immunogenicity.

30 The term “immunoglobulin” is used herein to refer to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized

- 33 -

immunoglobulin genes include the κ , λ , α , γ (IgG₁, IgG₂, IgG₃, IgG₄), δ , ϵ and μ constant region genes, as well as the myriad immunoglobulin variable region genes. One form of immunoglobulin constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light
5 and one heavy chain. In each pair, the light and heavy chain variable regions are together responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions. In addition to antibodies, immunoglobulins may exist in a variety of other forms including, for example, Fv, Fab, Fab' and (Fab')₂.

10 Reference herein to "immuno-interactive" includes reference to any interaction, reaction, or other form of association between molecules and in particular where one of the molecules is, or mimics, a component of the immune system. An "immunointeractive molecule" includes an antibody, antibody fragment, synthetic antibody or a T-cell associated binding molecule (TABM).

15

By "isolated" is meant material that is substantially or essentially free from components that normally accompany it in its native state.

A sample of biological fluid that is isolated from, or derived from, a particular source of
20 the host is described as being "obtained from".

The invention also contemplates the use and generation of fragments of monoclonal antibodies produced by the method of the present invention including, for example, Fv, Fab, Fab' and F(ab')₂ fragments. Such fragments may be prepared by standard methods as
25 for example described by Coligan *et al.* (1991-1997, *supra*).

The present invention also contemplates synthetic or recombinant antigen-binding molecules with the same or similar specificity as the monoclonal antibodies of the invention. Antigen binding molecules of this type may comprise a synthetic stabilized Fv
30 fragment. Exemplary fragments of this type include single chain Fv fragments (sFv, frequently termed scFv) in which a peptide linker is used to bridge the N terminus or C

- 34 -

terminus of a V_H domain with the C terminus or N-terminus, respectively, of a V_L domain. ScFv lack all constant parts of whole antibodies and are not able to activate complement. Suitable peptide linkers for joining the V_H and V_L domains are those which allow the V_H and V_L domains to fold into a single polypeptide chain having an antigen binding site with
5 a three dimensional structure similar to that of the antigen binding site of a whole antibody from which the Fv fragment is derived. Linkers having the desired properties may be obtained by the method disclosed in U.S. Patent No 4,946,778. However, in some cases a linker is absent. ScFvs may be prepared, for example, in accordance with methods outlined in Krebber *et al.* (1997, *supra*). Alternatively, they may be prepared by methods described
10 in U.S. Patent No 5,091,513, European Patent No 239,400 or the articles by Winter and Milstein (*Nature* 349: 293, 1991) and Plückthun *et al.* (In *Antibody engineering: A practical approach* 203-252, 1996).

Alternatively, the synthetic stabilised Fv fragment comprises a disulphide stabilized Fv
15 (dsFv) in which cysteine residues are introduced into the V_H and V_L domains such that in the fully folded Fv molecule the two residues will form a disulphide bond therebetween. Suitable methods of producing dsFv are described, for example, in (Glockshuber *et al.*, *Biochem.* 29: 1363-1367, 1990; Reiter *et al.*, *J. Biol. Chem.* 269: 18327-18331, 1994; Reiter *et al.*, *Biochem.* 33: 5451-5459, 1994; Reiter *et al.*, *Cancer Res.* 54: 2714-2718,
20 1994; Webber *et al.*, *Mol. Immunol.* 32: 249-258, 1995).

Also contemplated as synthetic or recombinant antigen-binding molecules are single variable region domains (termed dAbs) as, for example, disclosed in (Ward *et al.*, *Nature* 341: 544-546, 1989; Hamers-Casterman *et al.*, *Nature* 363: 446-448, 1993; Davies &
25 Riechmann, *FEBS Lett.* 339: 285-290, 1994).

Alternatively, the synthetic or recombinant antigen-binding molecule may comprise a “minibody”. In this regard, minibodies are small versions of whole antibodies, which encode in a single chain the essential elements of a whole antibody. Suitably, the minibody
30 is comprised of the V_H and V_L domains of a native antibody fused to the hinge region and

- 35 -

CH3 domain of the immunoglobulin molecule as, for example, disclosed in U.S. Patent No 5,837,821.

5 In an alternate embodiment, the synthetic or recombinant antigen binding molecule may comprise non-immunoglobulin derived, protein frameworks. For example, reference may be made to Ku & Schutz (*Proc. Natl. Acad. Sci. USA* 92: 6552-6556, 1995) which discloses a four-helix bundle protein cytochrome b562 having two loops randomized to create complementarity determining regions (CDRs), which have been selected for antigen binding.

10

The synthetic or recombinant antigen-binding molecule may be multivalent (i.e. having more than one antigen binding site). Such multivalent molecules may be specific for one or more antigens. Multivalent molecules of this type may be prepared by dimerization of two antibody fragments through a cysteinyl-containing peptide as, for example disclosed by 15 (Adams *et al.*, *Cancer Res.* 53: 4026-4034, 1993; Cumber *et al.*, *J. Immunol.* 149: 120-126, 1992;). Alternatively, dimerization may be facilitated by fusion of the antibody fragments to amphiphilic helices that naturally dimerize (Plünckthun, *Biochem.* 31: 1579-1584, 1992) or by use of domains (such as leucine zippers jun and fos) that preferentially heterodimerize (Kostelny *et al.*, *J. Immunol.* 148: 1547-1553, 1992). In further 20 embodiment, a multi-step process is employed such as first administering a deimmunized antibody and then an anti-antibody with, for example, a reporter molecule.

The present invention further encompasses chemical analogues of amino acids in the variant antibodies. The use of chemical analogues of amino acids is useful *inter alia* to 25 stabilize the molecules when administered to a subject. The analogues of the amino acids contemplated herein include, but are not limited to, modifications of side chains, incorporation of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.

30

- 36 -

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH₄; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; 5 trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH₄.

10 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide. 15

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4- 20 chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N- 25 bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by 30 alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

- 37 -

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, 5 phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or *D*-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 3.

TABLE 3

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
	aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine	Nmasn
			L-N-methylaspartic acid	Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl-carboxylate	Norb	L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
15	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
30	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva

- 39 -

	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgabu
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
5	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
10	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
15	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
20	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
25	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
30	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis

- 40 -

	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmtet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
5	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
10	D-N-methyltyrosine	Dnmtyr	N-methyl- <i>n</i> -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
15	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
20	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
25	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
	N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
30	carbamylmethyl)glycine		carbamylmethyl)glycine	

- 41 -

1-carboxy-1-(2,2-diphenyl- Nmbc
ethylamino)cyclopropane

5 Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-
bifunctional crosslinkers such as the bifunctional imido esters having $(\text{CH}_2)_n$ spacer groups
with $n=1$ to $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional
reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide
and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or
10 carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for
example, incorporation of C_α and N_α -methylamino acids, introduction of double bonds
between C_α and C_β atoms of amino acids and the formation of cyclic peptides or analogues
by introducing covalent bonds such as forming an amide bond between the N and C
termini, between two side chains or between a side chain and the N or C terminus.

15

A monoclonal antibody obtained before deimmunization may be identified by any number
of means including the steps of:-

- (a) coating a surface with antigen selected from cross-linked fibrin derivative or extract
20 containing same or fibrinogen degradation product;
- (b) contacting the antigen in step (a) with monoclonal antibody derived from fibrin
cross-linked derivative prepared as described above; and
- 25 (c) subjecting the complex formed in step (b) to a signal amplification step.

Suitably, in step (a), a well plate may be utilized in which cross-linked fibrin derivatives
such as D-dimer and/or fibrinogen degradation product (preferably obtained from a
procedure wherein fibrinogen was suitably digested with thrombin to obtain fragment D,
30 fragment E and optionally fragments X and Y) was applied to the individual wells.

- 42 -

Subsequently, monoclonal antibody derived from a cross-linked fibrin derivative was then added to each well. An appropriate signal amplification step which may be applied is an EIA step wherein an appropriate enzyme conjugate may be coupled to the complex and substrate subsequently added. Alternatively, RIA, FIA, agglutination, adherence or
5 chemiluminescence may be used as appropriate signal amplification steps.

The purpose of the screening assay procedure referred to above is to ensure that the cells being tested are producing antibody specific to the relevant cross-linked fibrin derivative, but not to fragment D.

10

There should be minimal reaction with fibrinogen or fibrinogen degradation products and a positive reaction with the derivative. The term "minimal" includes no reactivity but extends to basal levels such as compared to an antibody-directed to fibrinogen *per se*. Consequently, a minimal reaction includes sub-optimal reactivity compared to a
15 fibrinogen-specific antibody.

The present invention also includes within its scope an assay to detect linked fibrin derivatives including the steps of:-

- 20 (1) contacting a monoclonal antibody specific to cross-linked fibrin derivatives but not fragment D with a biological sample suspected of containing an antigen derived from a cross-linked fibrin derivative or comprising a cross-linked fibrin derivative *per se*; and
- 25 (2) subjecting the complex formed in step (1) to a signal amplification step.

In the above-mentioned assay, the cross-linked fibrin derivative is suitably D-dimer, D₂E or any other derivative of a high molecular weight nature as described above. The monoclonal antibody is prepared as described previously which is relevant to the particular
30 cross-linked fibrin derivative being assayed.

- 43 -

The presence of the cross-linked fibrin derivative may be used as a suitable diagnostic aid for prethrombotic, thrombotic or other conditions that involve the formation and lysis of fibrin.

- 5 The deimmunized monoclonal antibody of the present invention is particularly useful for blood clot imaging as well as for targeting blood clots in order to bring the clot into contact with enzymes or other chemical agents capable of dissolving, wholly or partially, the clot.

10 With respect to clot imaging, a reporter molecule is attached to the deimmunized monoclonal antibody or to an antibody having specificity for the deimmunized antibody or a portion or conjugate thereon and this is then introduced to a host, such as a human. By detecting the reporter molecule, blood clots can be visualized. One particularly useful form of reporter molecule is a nuclear tag. Nuclear tags contemplated for use in the present invention include but not limited to a bifunctional metal ion chelate. The chelate may be
15 attached to the antibody itself or multiple chelates may be attached to the protein *via* dendrimers. Particularly preferred nuclear tags are ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re . The most preferred nuclear tag is ^{99m}Tc . Preferably, the host is a human and, hence, it is necessary for the 3B6 murine monoclonal antibody to be deimmunized.

20

Alternative forms of immunoscintigraphy may be obtained using isotopes such as a ^{68}Ga or ^{124}I or other PET isotopes. Such technology may be described as "immuno-PET". The technology has advantages over γ camera scintigraphy and may provide high resolution images of blood clots especially in areas of the body less amenable to conventional
25 diagnostic means such as lungs or small clots in the calf or pelvis.

Accordingly, the present invention provides a conjugate molecule comprising a deimmunized immunointeractive molecule such as a deimmunized antibody and one or both of an imaging tag or a therapeutic agent.

30

Preferred imaging tags are MRI-, ultrasound- and/or CT-type tags such as but not limited

- 44 -

to ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .

Preferred therapeutic tags include cytokines, anti-clotting agents, wound-repairing agents and anti-infection agents.

5

Another aspect of the present invention contemplates a method for detecting a blood clot in a human patient, said method comprising introducing into said patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the
10 circulatory system and then subjecting said patient to reporter molecule-detection means to identify the location of the antibody in a clot.

Preferably, the reporter molecule is a nuclear tag.

15 Preferably, the nuclear tag is ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .

Preferably, the nuclear tag is ^{99m}Tc .

20 The present invention further contemplates the use of a deimmunized murine monoclonal antibody specific for D-dimer or other cross-linked fibrin derivatives in the manufacture of clot imaging agent.

Preferably, the murine monoclonal antibody is 3B6 or a homologue thereof.

25

Preferably, the clot imaging tag is for use in humans.

The same antibody may also carry multiple tags such as multiple anti-coagulant agents and/or reporter molecules. Alternatively, or in addition, multiple anti-antibodies may be
30 administered each carrying a different tag.

- 45 -

The present clot targeting antibody may be used alone or in combination with other imaging protocols. One such protocol is planar imaging such as but not limited to CT, MRI or ultrasound.

5 Accordingly, another aspect of the present invention contemplates a method for detecting a blood clot in a human patient, said method comprising introducing into said patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting said patient to planar clot imaging.

10

Preferably, the planar imaging is MRI or CT scanning. Ultrasound may also be used in the imaging process.

15 Accordingly, another aspect of the present invention contemplates a method for detecting a blood clot in a human patient, said method comprising introducing into said patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting said patient to a computer assisted tomographic nuclear medicine scan to visualize the clot.

20

Preferably, the reporter molecule is a nuclear tag.

Preferably, the nuclear tag is ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .

25

Preferably, the nuclear tag is ^{99m}Tc .

30 The clot imaging agents of the present invention are also useful as therapeutic agents. In particular, the clot targeting agents are fused, bound or otherwise associated with a clot dissolution or clot growth prevention agent such as an anticoagulant molecule.

- 46 -

Accordingly, another aspect of the present invention contemplates a method for facilitating the dissolution or removal of a blood clot in a human, said method comprising administering to said human a clot dissolution or clot growth prevention-effective amount of a variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant
5 murine-derived monoclonal antibody is substantially non-immunogenic in a human wherein said monoclonal antibody further comprises a clot dissolution or clot growth prevention agent fused, bound or otherwise associated thereto.

10

Yet another aspect of the present invention is directed to the use of a variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant murine-derived monoclonal
15 antibody is substantially non-immunogenic in a human and said antibody further comprising a clot dissolution or clot growth prevention agent fused, bound or otherwise attached thereto in the manufacture of a medicament for the dissolution of a blot clot in a human.

20 In an alternative embodiment, multiple deimmunized antibodies may be used. In one example, a deimmunized 3B6 antibody is administered alone and then deimmunized anti-immunglobulin antibodies each carrying an agent such as a diagnostic or therapeutic agent which will target a clot-3B6 complex. Yet another alternative is to engineer antibodies with multiple (e.g. bi-) specificities. In this case, one specificity may be to the clot and
25 another to the site of the clot (e.g. to a cell receptor). This may also be accomplished using multiple antibodies.

The present invention further contemplates compositions comprising the clot targeting agents of the present invention and one or more pharmaceutically acceptable carriers
30 and/or diluents.

- 47 -

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions as well as lyophilized forms of antibody preparations together with stabilizing agents such as sugar, proteins or other compounds or molecules which facilitate the radiolabeling process. It must be stable under the conditions of manufacture and storage and must be
5 preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dilution medium comprising, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of surfactants. The preventions of the action of microorganisms
10 can be brought about by various anti-bacterial and anti-fungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and
15 gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with the active ingredient and optionally other active ingredients as required, followed by filtered sterilization or other appropriate means
20 of sterilization.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active
25 substances is well known in the art and except insofar as any conventional media or agent is incompatible with the active ingredient, their use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

30 The clot targeting agents of the present invention are useful for the diagnosis and/or treatment of thrombin-associated conditions such as DVT, PE and DIC.

- 48 -

Yet another aspect of the present invention contemplates a method for treating a subject with cancer associated with fibrin. In this embodiment, antibodies to the D-dimer epitope may be used to deliver cytotoxic agents such as an isotope that emits β or γ emission or combinations thereof. Such isotopes include but are not limited to ^{131}I , yttrium-90, rhenium-186, rhenium-188, lutetium-117 and copper-67. Fibrin associated with a cancer includes a fibrin encapsulated tumor.

The deimmunized immunointeractive molecules of the present invention are, therefore, carriers for any clot binding agents or clot dissolving agents or for any agents which have useful diagnostic or therapeutic properties. The deimmunized immunointeractive molecules of the present invention are also useful for determining the kinetics of clot dissolution, dissipation and/or disappearance. Once this information is available, clot dissolving or imaging agents can very quickly be administered.

15

The present invention is further described by the following non-limiting Examples.

- 49 -

EXAMPLE 1

Cell fusion and selection of hybrids

Spleens were removed aseptically from 2 immunized mice killed by cervical dislocation
5 three days after an injection of D-dimer. Previously, the mice had been immunized with
three injections of fibrin lysate digested with proteolytic enzymes thrombin and plasmin as
reported in the aforementioned Graeff and Hafter reference. Two spleens were placed in a
60 mm Petri dish (Falcon, 3001, Oxnard, Calif.) containing 5 ml complete medium (85%
RPMI 1640, 15% w/v fetal calf serum, 100 I.U./ml penicillin, 100 µg/ml streptomycin and
10 2×10^{-3} M glutamine; Gibco, Grand Island, N.Y.). A cell suspension was prepared by
decapsulating the spleen with 2 x 18 gauge needles attached to 3 ml disposable syringes
with the last cm of the tip bent through an angle of 60°. The cell suspension was then
aspirated into a 10 ml syringe fitted with a 22 gauge needle and ejected with moderate
pressure. This operation was performed twice before filtering the cells into a Falcon 2001
15 tube through a fine mesh stainless steel screen to remove larger cell clumps and debris.

The cell suspension was allowed to stand for 5 minutes at room temperature to allow
smaller clumps and membrane fragments to settle before transferring the cell suspension to
a fresh Falcon 2001 tube. The cells were centrifuged at 350G for 5 minutes at room
20 temperature and the supernatant was decanted from the first cell pellet to a fresh tube and
spun at 700G for five minutes to give a second cell pellet and the two pellets were pooled
and resuspended in 5 ml complete medium. The spleen white blood cells (SWBC) were
then counted and their viability estimated by Turks and Trypan blue stains, respectively,
and 100×10^6 viable SWBC were placed in separate Falcon 2001 tubes in a total volume of
25 5 ml complete medium. The NS-1 myeloma cells to be used for fusion, were washed once
by centrifugation at 380G for 15 minutes at room temperature and adjusted to 5×10^6
viable cells/ml in complete medium.

Twenty-five $\times 10^6$ NS-1 and 100×10^5 immune SWBC were mixed and spun at 350G for 5
30 minutes at room temperature. The supernatant was decanted, the remaining medium was
carefully removed with a Pasteur pipette and 2 ml of a 42% w/v solution of polyethylene

- 50 -

glycol (PEG, MW1540) (Baker Chemical Co., New Jersey). In RPMI 1640 containing 15% v/v dimethyl sulfoxide (DMSO) at 37°C was added with a 5 ml glass disposable pipette (Corning Glass, Corning, NY) and the cells were resuspended with the same 5 ml pipette for 30 seconds with the aid of an electric pipetter (Pipet-aid Drummond Scientific Co., Broomall, PA). The PEG-cell suspension was allowed to stand for a further 30 seconds at room temperature before adding 5 ml complete medium, dropwise, with a Pasteur pipette, over a period of 90 seconds with constant flicking of the tube, sufficient to ensure complete mixing with the viscous PEG solution. A further 5 ml complete medium was immediately added and mixed by inversion and the cell suspension was allowed to stand for a further 150 seconds at room temperature before centrifugation at 350G for 5 minutes at room temperature. The supernatant was decanted and the cell pellet was gently resuspended in 5 ml complete medium using a 5 ml pipette with the electric pipetter; extreme care was taken not to break up all cell clumps. Using a Tridak stepper (Bellco Glass Inc., Vineland, NJ), 0.05 ml of the cell suspension was added to each well of 4 Costar 24 well plates (Costar 3524, Cambridge, Mass.) containing 1×10^6 normal BALB/c mouse SWBC as feeder cells in 1 ml complete medium containing 10^{-4} M Hypoxanthine (Sigma), 4×10^{-7} M Aminopterin (Sigma), 1.6×10^{-5} M Thymidine (Sigma) and 4×10^{-5} M 2-Mercaptoethanol (HAT medium), hereinafter referred to as 1° fusion plates.

The 1° fusion plates were then placed in a humidified 5% CO₂ 95% air atmosphere at 37°C. The cells were first fed either on days 5 or 7 and thereafter when necessary, with 0.5 ml fresh HAT medium. Generally, on day 10, 0.5 ml of the medium was removed for the screening assay from each well showing hybridoma growth and 0.5 ml fresh HAT medium was replaced. A number of the strongest growth wells were chosen for maintenance on the basis of the screening assay. The chosen wells were allowed to grow to confluency in the original original well (1° well), then each was split in half and transferred to a fresh well (2° well) of a 24 well Costar plate (2° plate). The wells were checked daily and expanded to a second, third or fourth well of the 2° Costar plate when necessary. From days 14-28, cells were fed with HT medium. When there was strong growth in at least two wells of the 2° plate, supernatant from one well of each clonotype was chosen for rescreening and a number of specific antibody producing clonotypes were chosen from the results of the

- 51 -

second screening assay to produce monoclonal antibody secreting cell lines by limiting dilution.

EXAMPLE 2

5 *Cloning of hybridomas*

One 2° well of each chosen clonotype was resuspended and the number of viable cells per well was estimated by Trypan blue exclusion. Immediately before plating each clonotype, the relevant series of dilutions were made in HT medium or complete medium (if the cells
10 were older than 28 days post fusion) to give a frequency of 0.5 cells/0.05 ml. This volume was then added with a Tridak stepper to each well of a 96 well flat bottomed tissue culture plate (Flow Laboratories, Mississauga, Ontario, Canada) (LD plate) containing 1×10^5 normal mouse spleen feeder cells in 0.1 ml HT or complete medium. the LD plates were then placed in a 37°C humidified 5% CO², 95% air atmosphere and screened for clonal
15 growth 7-10 days later. From each positive growth well, 0.1 ml supernatant was removed for screening and these wells were fed for the first time with 0.1-0.15 ml HT or complete medium. On the basis of the LD screening assay, a minimum of two of the “better” specific antibody-producing clones were finally selected for expansion to mass culture.

20 Alternatively, if it was desired to obtain a large amount of Mab, female BALB/c mice were given an intraperitoneal injection of 0, 5 ml 2, 5, 10, 14, tetramethylpentadecane (Pristane, Aldrich Chemical Corp., Milwaukee, Wisconsin) 14 days prior to the injection of 2×10^6 viable hybridoma cells and ascites fluids were collected from the mice 12-14 days after injection of the cells. The ascitic fluid was clarified by centrifugation and MAb recovered
25 by precipitation with 45% ammonium sulphate and stored at either 4°C or -70°C in phosphate buffered saline (PBS) containing 0.01% sodium azide.

EXAMPLE 3

Monoclonal antibody screening assay

30

The wells of a 96 well U bottomed microtest plate (Disposable Products Pty. Ltd.,

- 52 -

Adelaide, South Australia) were coated by adding 50 μ l of either D-dimer (5 μ g/ml) or Fibrinogen degradation products (5 μ g/ml in PBS for one hour at room temperature (25°C). Excess antigen was removed by inverting and tapping the plate and the plate was then washed three times with PBS containing 0.05% w/v Tween 20 (Sigma Chemical Corp., St Louis, Missouri). Clones secreting MAb to D-dimer or Fibrinogen degradation products were then detected by adding 50 μ l of tissue culture supernatant to each well and incubating for one hour at room temperature. Unbound MAb was removed by inversion and tapping and the plate was washed three times with PBS/Tween. One hundred μ l of a $1/1000$ dilution of peroxidase conjugated rabbit anti-mouse immunoglobulin (Dakopatts, Copenhagen, Denmark) in PBS/Tween was added and allowed to incubate a further one hour at room temperature. The plate was again inverted and washed three times with PBS/Tween and 100 μ l of activated substrate (immediately before use, 10 μ l of 3% solution of hydrogen peroxide was added to 10 ml of a substrate solution containing 50 mM citrate, 2.5 mM of o-tolidine dihydrochloride (o-tolidine, Sigma Chemical Co., recrystallized from dilute HCl) 0.025 mM EDTA pH 4.5) was added to each well. The colour reaction was stopped after 10 minutes by the addition of 50 μ l of 3M HCl which caused a colour change from blue to yellow and the absorbance was recorded at 450 nm on a Titertek multiskan.

20

EXAMPLE 4

Identification of 3B6 variable region sequences

The murine hybridoma 3B6 was propagated in RPMI 1640 medium supplemented with 15% w/v fetal calf serum. Total RNA was prepared from 10^7 hybridoma cells. V_H and V_K cDNA was prepared using reverse transcriptase and mouse κ constant region and mouse IgG constant region primers. The first strand cDNAs were amplified by PCR using a variety of mouse signal sequence primers (6 sets for V_H and 7 sets for V_K). The amplified DNAs were gel-purified and cloned into the vector pGem® T Easy (Promega). The V_H and V_K clones obtained were screened for inserts of the expected size by PCR and the DNA sequence of selected clones determined by the dideoxy chain termination method.

30

- 53 -

Productive V_H and V_K genes were identified by sequence analysis. The location of the complementarity determining regions (CDRs) was determined with reference to other antibody sequences (43). The 3B6 V_H can be assigned to mouse heavy chains sub-group IA. The 3B6 V_K can be assigned to mouse κ chains sub-group I.

5

EXAMPLE 5

Analysis of 3B6 variable (v) region sequences with potential T cell epitopes

3B6 V_H and V_K sequences were analyzed for the presence of potential T cell epitopes using procedures described previously (Carr *et al.*, International Patent Publication No. WO 98/52976). The peptides identified as potential T cell epitopes (MHC class II binding peptides) were modified *in silico* and the modified sequence re-analyzed to ensure loss of potential MHC class II binding and verify that further MHC class II binding motifs had not been generated in the surrounding sequence. Alternatively, the sequence was modified to convert the MHC class II binding motif to one found in the human germ line. Single, generally conservative, amino acid substitutions were tested and substitutions made with due regard to overall antibody structure. A number of variant sequences are compiled for the V_H and V_K , each containing different numbers of substitutions.

15
20

EXAMPLE 6

Designer variant 3B6 variable (v) regions sequences with reduced numbers of potential T cell epitopes

The heavy and light (v) regions designed according the scheme of Example 5 were constructed *in vitro* by the method of overlapping PCR recombination described (Daugherty *et al.*, *Nucleic Acids Research* 19: 2471-2476, 1991). The cloned murine V_H and V_K genes were used as templates for mutagenesis of the framework regions to the required humanized sequences. Sets of mutagenic primer pairs were synthesized encompassing the regions to be altered. Adjacent primers included 15 bp of homologous sequence. A first round of PCR using these primers produced 5 to 8 overlapping DNA fragments encompassing the designed (v) region gene. The vectors V_H -PCR1 and V_K -

25
30

- 54 -

PCR1 (Orlandi *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 3833-3837, 1989) were used as templates to introduce 5' flanking sequence including the leader signal peptide, leader intron and the murine immunoglobulin promoter, and 3' flanking sequence including the splice site and intron sequences, in an additional two overlapping fragments. The DNA fragments produced were combined in a second round of PCR using outer flanking primers to obtain PCR products of the required full length. These PCR products were cloned into the vector pUC19 for DNA sequence determination. Clones were selected that contained the expected sequence alterations and the entire DNA sequence was confirmed to be correct for each desired V_H and V_K . The heavy and light chain genes were transferred to the expression vectors pSVgpt and pSVhyg with human IgG1 or κ constant regions as described (Tempest *et al.*, *Biotechnology* 9: 266-271, 1991). The vectors V_H -PCR1 and V_K -PCR1 (Orlandi *et al.*, 1989, *supra*) were used as templates to introduce 5' flanking sequence including the leader signal peptide, leader intron and the murine immunoglobulin promoter, and 3' flanking sequence including the splice site and intron sequences.

15

EXAMPLE 7

Expression and purification of variant 3B6 antibodies

The variant 3B6 heavy and light chain expression vectors were co-transfected in different combinations by electroporation into NS0, a non-immunoglobulin producing mouse myeloma, obtained from the European Collection of Animal Cell Cultures, Porton, U.K. (ECACC No 85110505). Colonies expressing the *gpt* gene were selected in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 0.8 $\mu\text{g/ml}$ mycophenolic acid and 250 $\mu\text{g/ml}$ xanthine. Production of human antibody by transfected cell clones was measured by ELISA for human IgG (48). Cell lines secreting antibody were selected and expanded. Variant 3B6 antibodies were purified using Prosep®-A (Bioprocessing Ltd, Conset, U.K.).

25

EXAMPLE 8

Functional testing of variant 3B6 antibodies

Variant antibodies were tested for D-dimer binding using ELISA based assays broadly as

- 55 -

described in Example 3. Binding specificity was confirmed using the human fibrinogen binding assay. In a preferred embodiment, however, the D-dimer was used in solution phase. In this assay, the 3B6 antibodies were coated on the ELISA plate at 0.5 $\mu\text{g}/\text{well}$, to capture D-dimer in solution. D-dimer was applied at 10 $\mu\text{g}/\text{ml}$ (500 ng/well) and doubling dilutions. The revealing antibody was HRPO conjugated mouse monoclonal anti-D (Dimertest EIA Tag; Agen) and the results were developed by OPD substrate and read a 492 nm. The deimmunized 3B6 antibodies are compared to the murine and chimeric 3B6 antibodies and the previous lead deimmunized antibody 3B6 DIVH1/DIVK1. The results are shown in Figures 4A, 4B and 4C. The use of solution phase D-dimer proved better than solid phase D-dimer in the selection of clones and is a preferred aspect of the present invention.

EXAMPLE 9

Thromboviewing using 3B6-^{99m}Tc

15

The 3B6 monoclonal antibody from mice and deimmunized form for humans is represented in Figure 1A and exhibits specificity for fibrin which is a major part of blood clots (Figure 1B). A clot imaging concept is developed by labelling the 3B6 monoclonal antibody with a nuclear tag, in this case, ^{99m}Tc (Figure 2). Administration of the labeled 3B6 deimmunized monoclonal antibody in humans (Figure 3A). Visualization of clots in the circulatory system such as blood clots in the anterior thighs (Figure 3B) occurs by binding of the monoclonal antibody to fibrin resulting in concentration of radiation at the clot site.

25

EXAMPLE 10

Thromboviewing using 3B6-^{99m}Tc

Pulmonary emboli (0.1-0.5 g) were created in anesthetized dogs by embolization of pre-formed thrombi made by infusion of thrombin and human fibrinogen through balloon catheters placed in the femoral veins. Purified Fab' fragments (0.35 mg) of a chimeric (human/murine) derivative of a fibrin-specific monoclonal antibody were labeled with a 15

- 56 -

mCi of ^{99m}Tc . One hour after embolization, the radiolabeled antibody preparation was injected through a peripheral intravenous catheter. Eight hours after antibody injection, imaging scans were performed to visualize the emboli.

5 ^{99m}Tc labeled antibody fragments cleared from the circulation with a $t_{1/2}$ of one hour for both subjects. In subject 1, two small emboli in the right lower lobe (combined mass, 0.187 g) were visible. The clot/blood radioactivity ratio was 38:1. In subject 2, one embolus in the right lower lobe (mass, 0.449 g) was visible. Clot/blood radioactivity ratio was 27:2. A small embolus (0.091 g) was discovered in the right ventricle of subject 1. The clot/blood
10 radioactivity ratio was 45:1. No adverse effects were noted from either antibody administration or scanning methodology.

Infusion of radiolabeled anti-fibrin antibody fragments followed by imaging produces images of emboli, even relatively small emboli in the periphery of the lung. The
15 images are reliable and require minimal training to interpret. The technique can be used to image deep vein thrombi in the same setting. This agent is well tolerated by the subjects. There is no need for breath-holding or cardiac gating. It uses no nephrotoxic intravenous contrast dye. The radiation dose is similar to the dose used for ventilation/perfusion scans. This technology may simplify and clarify the diagnosis of PE and DVT, using technology
20 available in most medical centres.

Those skilled in the art will appreciate that the invention described herein is susceptible to
25 variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

30

BIBLIOGRAPHY

Adams *et al.*, *Cancer Res.* 53: 4026-4034, 1993.

Altschul *et al.*, *Nucl. Acids Res.* 25:3389-3402. 1997.

Ausubel *et al.*, "Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-1998, Chapter 15.

Budzynski *et al.*, *Blood* 54(4), 1979.

Carr *et al.* (International Patent Publication No. WO 98/52976).

Chothia *et al.*, *J. Mol. Biol.* 196: 901, 1987.

Chothia *et al.*, *J. Mol. Biol.* 227: 799, 1992.

Chou *et al.* (U.S. Patent No. 6,056,957).

Coligan *et al.*, *Current Protocols in Immunology*, John Wiley & Sons, Inc., 1991-1997.

Cumber *et al.*, *J. Immunol.* 149: 120-126, 1992.

Daugherty *et al.*, *Nucleic Acids Research* 19: 2471-2476, 1991.

Davies & Riechmann, *FEBS Lett.* 339: 285-290, 1994.

European Patent Publication No. 0 239 400.

Gefter *et al.*, *Somatic Cell Genet.* 3: 231-236, 1977.

- 58 -

Glockshuber *et al.*, *Biochem. 29*: 1363-1367, 1990.

Graeff and Halfer, "Detection and Relevance of Cross-linked Fibrin Derivatives in Blood", *Seminars in Thrombosis and Hemostasis 8(1)*, 1982.

Hamers-Casterman *et al.*, *Nature 363*: 446-448, 1993.

Jones *et al.*, *Nature 321*: 522-525, 1986.

Kabat *et al.*, "Sequences of Proteins of Immunological Interest", U.S. Department of Health and Human Services, 1983.

Kennet *et al.* (eds) *Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses*, pp. 376-384, Plenum Press, New York, 1980.

Kohler and Milstein, *Eur. J. Immunol. 6(7)*: 511-519, 1976.

Kohler and Milstein, *Nature 256*: 495-499, 1975.

Kostelny *et al.*, *J. Immunol. 148*: 1547-1553, 1992.

Kozbor *et al.*, *Methods in Enzymology 121*: 140, 1986.

Krebber *et al.*, *J. Immunol. Methods 201(1)*: 35-55, 1997.

Ku & Schutz, *Proc. Natl. Acad. Sci. USA 92*: 6552-6556, 1995.

Liu *et al.*, *Proc. Natl. Acad. Sci. USA 84*: 3439-3443, 1987.

Morgan *et al.* (U.S. Patent No. 6,180,377).

- 59 -

Orlandi *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 3833-3837, 1989.

Plückthun *et al.*, In *Antibody engineering: A practical approach* 203-252, 1996.

Plünckthun, *Biochem.* 31: 1579-1584, 1992.

Queen *et al.* (U.S. Patent No. 6,180,370).

Reiter *et al.*, *Biochem.* 33: 5451-5459, 1994.

Reiter *et al.*, *Cancer Res.* 54: 2714-2718, 1994.

Reiter *et al.*, *J. Biol. Chem.* 269: 18327-18331, 1994.

Riechmann *et al.*, *Nature* 332: 323-327, 1988.

Shulman *et al.*, *Nature* 276: 269-270, 1978;

Tempest *et al.*, *Biotechnology* 9: 266-271, 1991.

Toyama *et al.*, "*Monoclonal Antibody, Experiment Manual*", published by Kodansha Scientific, 1987.

Trowbridge, *J. Exp. Med.* 148(1): 313-323, 1978.

Verhoeyen *et al.*, *Science* 239: 1534-1536, 1988.

Volk *et al.*, *J. Virol.* 42(1): 220-227, 1982.

Ward *et al.*, *Nature* 341: 544-546, 1989.

- 60 -

Webber *et al.*, *Mol. Immunol.* 32: 249-258, 1995.

Willner *et al.*, *Biochemistry* 21: 2687-2692, 1982.

Winter and Milstein, *Nature* 349: 293, 1991,

CLAIMS

1. A variant of an immunointeractive molecule, said variant comprising a portion having specificity for cross-linked fibrin derivatives and which portion is derived from an immunointeractive molecule obtainable from one animal or avian creature wherein said variant exhibits reduced immunogenicity in another animal or avian creature from the same or different species.
2. The variant immunointeractive molecule of Claim 1 wherein the immunointeractive molecule is an antibody.
3. The variant immunointeractive molecule of Claim 2 wherein the antibody is a monoclonal antibody.
4. The variant immunointeractive molecule of Claim 3 wherein a monoclonal antibody from a murine animal is deimmunized with respect to another murine animal or a non-murine species of animal.
5. The variant immunointeractive molecule of Claim 4 wherein the non-murine species of animal is a human.
6. The variant immunointeractive molecule of Claim 4 or 5 wherein the murine monoclonal antibody is raised in a murine animal to non-denatured D-dimer.
7. The variant immunointeractive molecule of Claim 6 wherein the D-dimer is of human origin.
8. A variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant murine-derived monoclonal antibody is substantially non-immunogenic in a

human.

9. The variant immunointeractive molecule of any one of Claims 1 to 7 or the variant murine monoclonal antibody of Claim 8 wherein the variant is of murine monoclonal 3B6.

10. A deimmunized form of monoclonal antibody 3B6 wherein said deimmunized 3B6 is substantially non-immunogenic in humans.

11. A method for generating a deimmunized monoclonal antibody having specificity for antigenic determinants on human D-dimer or other cross-linked fibrin derivatives, said method comprising:-

- (i) obtaining a cross-linked fibrin derivative or extract containing same from a human;
- (ii) generating an antibody in a non-human animal specific to said cross-linked fibrin derivative but which does not cross-react with fragment D; and
- (iii) subjecting said non-human derived antibody to deimmunization means.

12. A deimmunized antibody molecule having specificity for an epitope recognized by monoclonal antibody 3B6 wherein at least one of the complementary determining regions (CDRs) of the variable domain of said deimmunized antibody is derived from the said 3B6 monoclonal antibody and the remaining immunoglobulin-derived parts of the deimmunized antibody molecule are derived from an immunoglobulin or an analogue thereof from the host for which the antibody is to be deimmunized.

13. The deimmunized antibody of Claim 12 wherein said antibody is a

- 63 -

humanized form of murine monoclonal antibody 3B6.

14. The deimmunized antibody of Claim 13 comprising one or more amino acid mutations in the v-region of said 3B6 antibody to eliminate or reduce peptide fragments of said v-region associating with MH class II molecules.

15. The deimmunized antibody of Claim 13 or 14 wherein the antibody is derived from different combinations of H-chain and L-chain genes.

16. The deimmunized antibody of Claim 15 wherein the H-chains are selected from Hv5 (3B6DIVHv5; SEQ ID NO:1), Hv6 (3B6DIVHv6; SEQ ID NO:2) and Hv7 (3B6DVIHv7; SEQ ID NO:3).

17. The deimmunized antibodies of Claim 15 wherein the L-chains are selected from Kv1 (3B6DIVKv1; SEQ ID NO:4), Kv4 (3B6DIVKv; SEQ ID NO:5) and Kv7 (3B6DIVKv7; SEQ ID NO:6).

18. The deimmunized antibodies of Claim 16 or 17 wherein the variants comprises a combination of H-chains and L-chains selected from VHv5/VKv1, VHv6/VKv1, VHv7/VKv1, VHv5/VKv7, VHv6/VKv7, VHv6/VKv4, VHv7/VKv4, VHv7/VKv7 and VHv5/VKv4.

19. A variant murine monoclonal antibody 3B6 deimmunized for use in humans, said variant comprising a combination of heavy and light chain v-regions comprising the amino acid sequences encoded by nucleotide sequences selected from SEQ ID NO:7/SEQ ID NO:10, SEQ ID NO:8/SEQ ID NO:10, SEQ ID NO:9/SEQ ID NO:10, SEQ ID NO:7/SEQ ID NO:12, SEQ ID NO:8/SEQ ID NO:12, SEQ ID NO:8/SEQ ID NO:11, SEQ ID NO:9/SEQ ID NO:11, SEQ ID NO:9/SEQ ID NO:12 and SEQ ID NO:7/SEQ ID NO:11 or combinations of amino acid sequences encoded by nucleotide sequences having at least 70% similarity to one or both amino acid sequences in each of the above listed pairs or nucleotide sequences capable of hybridizing to low stringency

- 64 -

conditions to one or both nucleotide sequences or their complementary forms in each of the above listed pairs.

20. A variant of a murine monoclonal antibody 3B6 deimmunized for use in humans, said variant comprising a combination of heavy and light chain v-regions comprising the amino acid sequences selected from SEQ ID NO:1/SEQ ID NO:4, SEQ ID NO:2/SEQ ID NO:4, SEQ ID NO:3/SEQ ID NO:4, SEQ ID NO:1/SEQ ID NO:6, SEQ ID NO:2/SEQ ID NO:6, SEQ ID NO:2/SEQ ID NO:5, SEQ ID NO:3/SEQ ID NO:5, SEQ ID NO:3/SEQ ID NO:6 and SEQ ID NO:1/SEQ ID NO:5 or combinations of amino acid sequences having at least 70% similarity to one or both amino acid sequences in each of the above listed pairs.

21. A method for detecting a blood clot in a human patient, said method comprising introducing into said patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting said patient to a computer assisted tomographic nuclear medicine scan to visualize the clot.

22. The method of Claim 21 wherein the reporter molecule is a nuclear tag.

23. The method of Claim 22 wherein the nuclear tag is ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .

24. The method of Claim 23 wherein the nuclear tag is ^{99m}Tc

25. The method of Claim 21 wherein the murine monoclonal antibody is 3B6 or a homolog thereof.

26. A method for detecting a blood clot or an antigen-binding fragment thereof, allowing dissemination of the antibody throughout the circulatory system, administering a

- 65 -

second antibody specific for said first mentioned antibody and labeled with a reporter molecule and then subjecting said patient to a computer assisted tomographic nuclear medicine scan to visualize the clot.

27. The method of Claim 26 wherein the reporter molecule is a nuclear tag.

28. The method of Claim 27 wherein the nuclear tag is ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .

29. The method of Claim 28 wherein the nuclear tag is ^{99m}Tc .

30. The method of Claim 26 wherein the murine monoclonal antibody is 3B6 or a homolog thereof.

31. A method for detecting a blood clot in a human patient, said method comprising introducing into said patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting said patient to planar clot imaging.

32. The method of Claim 31 wherein the planar imaging is MRI, CT scanning or ultrasound.

33. A method for detecting a blood clot in a human patient, said method comprising introducing into said patient a deimmunized form of murine monoclonal antibody 3B6 or an antigen-binding fragment thereof labeled with a reporter molecule allowing dissemination of the labeled antibody throughout the circulatory system and then subjecting said patient to a computer assisted tomographic nuclear medicine scan to visualize the clot.

34. The method of Claim 33 wherein the reporter molecule is a nuclear tag.

35. The method of Claim 34 wherein the nuclear tag is ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .
36. The method of Claim 35 wherein the nuclear tag is ^{99m}Tc .
37. The method of Claim 33 wherein the murine monoclonal antibody is 3B6 or a homolog thereof.
38. A method for detecting a blood clot or an antigen-binding fragment thereof, allowing dissemination of the antibody throughout the circulatory system, administering a second antibody specific for said first mentioned antibody and labeled with a reporter molecule and then subjecting said patient to a computer assisted tomographic nuclear medicine scan to visualize the clot.
39. The method of Claim 38 wherein the reporter molecule is a nuclear tag.
40. The method of Claim 39 wherein the nuclear tag is ^{99m}Tc .
41. The method of Claim 38 wherein the murine monoclonal antibody is 3B6 or a homolog thereof.
42. A method for facilitating the dissolution or removal of a blood clot in a human, said method comprising administering to said human a clot dissolution or clot growth prevention-effective amount of a variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant murine-derived monoclonal antibody is substantially non-immunogenic in a human wherein said monoclonal antibody further comprises a clot dissolution or clot growth prevention agent fused, bound or otherwise associated thereto.

- 67 -

43. Use of a variant murine-derived monoclonal antibody having specificity for human-derived D-dimer and other cross-linked fibrin derivatives and non-reactivity with fibrinogen or fibrinogen degradation products inclusive of fragments D and E wherein said variant murine-derived monoclonal antibody is substantially non-immunogenic in a human and said antibody further comprising a clot dissolution or clot growth prevention agent fused, bound or otherwise attached thereto in the manufacture of a medicament for the dissolution of a blot clot in a human.
44. A conjugate comprising an immunointeractive molecule and one or both of an imaging tag and/or a therapeutic agent.
45. The conjugate of Claim 44 wherein the imaging tag is an MRI-, ultrasound- or CT-type tag.
46. The conjugate of Claim 45 wherein the imaging tag is selected from ^{99m}Tc , ^{18}F , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , ^{97}Ru , ^{111}In , ^{123}I , ^{124}I , ^{131}I and ^{188}Re .
47. The conjugate of Claim 46 wherein the imaging tag is ^{99m}Tc .
48. The conjugate of Claim 44 wherein the therapeutic agent is an anti-clotting agent.
49. The conjugate of Claim 44 wherein the therapeutic agent is a cytokine.
50. The conjugate of any one of Claims 44 to 49 wherein the immunointeractive molecule is an antibody.
51. The conjugate of Claim 50 wherein the antibody is deimmunized 3B6.

1/7





Figure 1A



X4,200 magnification

Figure 1B




Figure 2




Figure 3A

4/7




Figure 3B




Figure 4A

6/7




Figure 4B

7/7




Figure 4C

- 1 -

SEQUENCE LISTING

<110> Agen Biomedical Limited (all designated States except US)
 Carr, Francis (US only)
 Hamilton, Anita (US only)

<120> Carrier molecules
 <130> 2537681/EJH

<140> International
 <141> 2000-06-26

<150> US 60/301,154
 <151> 2001-06-26

<150> US 60/300,947
 <151> 2001-06-27

<160> 12
 <170> PatentIn version 3.0

<210> 1
 <211> 118
 <212> PRT
 <213> peptide

<220>
 <221> misc_feature
 <222> ()..()
 <223> 3B6DIVHv5

<400> 1
 Asp Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
 20 25 30
 Tyr Ala Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
 35 40 45
 Met Gly Tyr Ile Thr Tyr Ser Gly Thr Thr Ser Tyr Asn Pro Ser Leu
 50 55 60
 Thr Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Phe
 65 70 75 80
 Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95
 Ala Arg Glu Trp Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Thr Leu Thr Val Ser Ser
 115

<210> 2

- 2 -

<211> 118
 <212> PRT
 <213> peptide

<220>
 <221> misc_feature
 <222> ()..()
 <223> 3B6DIVHv6

<400> 2
 Asp Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
 20 25 30
 Tyr Ala Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
 35 40 45
 Met Gly Tyr Ile Thr Tyr Ser Gly Thr Thr Ser Tyr Asn Pro Ser Leu
 50 55 60
 Thr Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Phe
 65 70 75 80
 Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95
 Ala Arg Glu Trp Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Thr Leu Thr Val Ser Ser
 115

<210> 3
 <211> 118
 <212> PRT
 <213> peptide

<220>
 <221> misc_feature
 <222> ()..()
 <223> 3B6DIVHv7

<400> 3
 Asp Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
 20 25 30
 Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
 35 40 45
 Met Gly Tyr Ile Thr Tyr Ser Gly Thr Thr Ser Tyr Asn Pro Ser Leu
 50 55 60

Thr Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Phe
65 70 75 80

Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Glu Trp Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Thr Leu Thr Val Ser Ser
115

<210> 4
<211> 107
<212> PRT
<213> peptide

<220>
<221> misc_feature
<222> ()..()
<223> 3B6DIVKv1

<400> 4
Asp Ile Val Met Thr Gln Ser Gln Lys Ser Met Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Ser Ile Ser Cys Lys Ala Ser Gln Asn Val Gly Thr Pro
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Thr Ser Thr Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Ala
65 70 75 80

Glu Asp Val Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Leu Tyr Pro Leu
85 90 95

Thr Phe Gly Ala Gly Thr Lys Val Glu Leu Lys
100 105

<210> 5
<211> 107
<212> PRT
<213> peptide

<220>
<221> misc_feature
<222> ()..()
<223> 3B6DIVKv4

<400> 5
Asp Ile Val Met Thr Gln Ser Gln Lys Ser Met Ser Thr Ser Val Gly
1 5 10 15

- 4 -

Asp Arg Val Ser Ile Ser Cys Lys Ala Ser Gln Asn Val Gly Thr Pro
 20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
 35 40 45

Tyr Ser Thr Ser Thr Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Ser
 65 70 75 80

Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Leu Tyr Pro Leu
 85 90 95

Thr Phe Gly Ala Gly Thr Lys Val Glu Leu Lys
 100 105

<210> 6
 <211> 107
 <212> PRT
 <213> peptide

<220>
 <221> misc_feature
 <222> ()..()
 <223> 3B6DIVKv7

<400> 6
 Asp Ile Val Met Thr Gln Ser Gln Lys Ser Met Ser Thr Ser Val Gly
 1 5 10 15

Asp Arg Val Ser Ile Ser Cys Lys Ala Ser Gln Asn Val Gly Thr Pro
 20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
 35 40 45

Tyr Ser Thr Ser Thr Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Ala
 65 70 75 80

Glu Asp Val Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Leu Tyr Pro Leu
 85 90 95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 100 105

<210> 7
 <211> 354
 <212> DNA
 <213> antibody

<220>

- 5 -

```

<221> misc_feature
<222> ()..()
<223> 3B6DIVHv5

<400> 7
gatgtgcagc ttaaggagtc gggacctggc ctggttaaac ctactcagac tctgaccctc      60
acctgcactg tcactggcta ctcaatcacc agtgattatg cctggaactg gatacggcag      120
ccaccaggaa agggactgga gtggatgggc tacataacct acagtggtag cactagctac      180
aaccatctc tcacaagtgc aatctctatc tctcgcgaca catccaagaa ccagttcttc      240
ctgcagttga attctctgac ttctgaggac acagccacat attactgtgc aagagagtgg      300
tttccttact actttgacta ctggggccaa ggcaccactc tcacagtctc ttca          354

<210> 8
<211> 354
<212> DNA
<213> antibody

<220>
<221> misc_feature
<222> ()..()
<223> 3B6DIVHv6

<400> 8
gatgtgcagc ttaaggagtc gggacctggc ctggttaaac ctactcagac tctgaccctc      60
acctgcactg tcactggcta ctcaatcacc agtgattatg cctggaactg gatacggcag      120
ccaccaggaa agggactgga gtggatgggc tacataacct acagtggtag cactagctac      180
aaccatctc tcacaagtgc aatctctatc tctcgcgaca catccaagaa ccagttcttc      240
ctgcagttga attctctgac ttctgaggac acagccacat attactgtgc aagagagtgg      300
tttccttact actttgacta ctggggccaa ggcaccactc tcacagtctc ttca          354

<210> 9
<211> 354
<212> DNA
<213> antibody

<220>
<221> misc_feature
<222> ()..()
<223> 3B6DIVHv7

<400> 9
gatgtgcagc ttaaggagtc gggacctggc ctggttaaac ctactcagac tctgaccctc      60
acctgcactg tcactggcta ctcaatcacc agtgattatg cctggaactg gatacggcag      120
tttccaggaa acaaactgga gtggatgggc tacataacct acagtggtag cactagctac      180

```


- 6 -

aacccatctc tcacaagtcg aatctctatc tctcgcgaca catccaagaa ccagttcttc 240
 ctgcagttga attctgtgac ttctgaggac acagccacat attactgtgc aagagagtgg 300
 tttccttact actttgacta ctggggocaa ggcaccactc tcacagtctc ttca 354

<210> 10
 <211> 321
 <212> DNA
 <213> antibody

<220>
 <221> misc_feature
 <222> ()..()
 <223> 3B6DIVKv1

<400> 10
 gacattgtga tgaccagtc tcaaaaatcc atgtccacat cagtaggaga cagggtcagc 60
 atctcctgca aggccagtca gaatgtgggt actcctgtag cctggtatca gcagaaacca 120
 gaacaatctc ctaaacttct gatttactcg acatccactc ggtaccctgg agtccctgat 180
 cgcttcaactg gcagtggatc tgggacagat ttcactctca ccatcagcaa tctgcaggct 240
 gaagacgtgg cagattatct ctgccagcaa tatagcctct atcctctcac gttcgggtgct 300
 gggaccaagg tggagctgaa a 321

<210> 11
 <211> 321
 <212> DNA
 <213> antibody

<220>
 <221> misc_feature
 <222> ()..()
 <223> 3B6DIVKv4

<400> 11
 gacattgtga tgaccagtc tcaaaaatcc atgtccacat cagtaggaga cagggtcagc 60
 atctcctgca aggccagtca gaatgtgggt actcctgtag cctggtatca gcagaaacca 120
 gaacaatctc ctaaacttct gatttactcg acatccactc ggtaccctgg agtccctgat 180
 cgcttcaactg gcagtggatc tgggacagat ttcactctca ccatcagcaa tctgcagtct 240
 gaagacctgg cagattatct ctgccagcaa tatagcctct atcctctcac gttcgggtgct 300
 gggaccaagg tggagctgaa a 321

<210> 12
 <211> 321
 <212> DNA
 <213> antibody

- 7 -


```
<220>
<221> misc_feature
<222> ()..()
<223> 3B6DIVKv7

<400> 12
gacattgtga tgaccagtc tcaaaaatcc atgtccacat cagtaggaga cagggtcagc      60
atctcctgca aggccagtca gaatgtgggt actcctgtag cctggtatca gcagaaacca      120
gaacaatctc ctaaacttct gatttactcg acatccactc ggtaccctgg agtcctgat      180
cgcttcactg gcagtggatc tgggacagat ttcactctca ccatcagcaa tctgcaggct      240
gaagacgtgg cagattatct ctgccagcaa tatagcctct atcctctcac gttcgggtgct      300
gggaccaagc tggagctgaa a                                             321
```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/00827

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : C07K 16/00, 16/18, 16/46; A61k 39/395; A61P 7/00, 7/02		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
Databases: Medline, Chem Abs, WPIDS, Biosis, Biotech Abs; Keywords: 3B6, fibrin, humanized		
Databases: GenPept, PIR, SWISS-PROT, TrEMBL; SEQ ID NOs: 1-6; BLASTP		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	BAUTOVICH G. <i>et al.</i> , "Detection of Deep Venous Thrombi and Pulmonary Embolus with Technetium-99m-DD-3B6/22 Anti-fibrin Monoclonal Antibody Fab' Fragment", Journal of Nuclear Medicine (1994), vol. 35, no. 2, pages 195-202 See whole document, in particular abstract, page 196 first column first complete paragraph, page 198 first column "Acute Toxicity Evaluation"	1-51
X, Y	US 4,758,524 (BUNDESEN <i>et al.</i>), 19 July 1988 See whole document	1-51
X, Y	WO 94/09034 A1 (AGEN LIMITED), 28 April 1994 See whole document, for example page 13 lines 22-35	1-51
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 8 July 2002		Date of mailing of the international search report 23 JUL 2002
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  O.L. CHAI Telephone No : (02) 6283 2482

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/00827

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	WO 91/02547 (AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION), 7 March 1991 See whole document, in particular abstract and page 2 lines 26-31	1-51
X, Y ----- Y	AGEN Media Release, 1 February 2001, as archived at http://web.archive.org/web/20010602122513/www.agen.com.au/news/mr011.htm See especially paragraph 2	1-15, 21-51 ----- 16-20
Y	WINTER G. and HARRIS W.J., "Humanized antibodies", Trends in Pharmacological Sciences (1993), vol. 14, no. 5, pages 139-143 See whole document	1-51
X	VANDAMME A.M. <i>et al.</i> , "Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase", European Journal of Biochemistry (1992), vol. 205, no. 1, pages 139-146 See whole document	1-8, 11, 26-29, 38-40, 42-50
X, Y	VANDAMME A.M. <i>et al.</i> , "Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment-D dimer", European Journal of Biochemistry (1990), vol. 192, no. 3, pages 767-775 See abstract, discussion	1-8, 11, 26-29, 38-40, 42-50
A	US 6,132,719 A (KOHNO <i>et al.</i>), 17 October 2000	
A	EP 0 347 933 B1 (RESEARCH CORPORATION TECHNOLOGIES INC.), 14 September 1994	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00827

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
US	4758524	AU	25387/84	CA	1247022	DK	1582/84
		EP	122478	ES	530691	ES	8507694
		GR	81951	IL	71264	IN	158324
		JP	59183696	NO	841023	NZ	207459
		PH	22957	PT	78267	ZA	8401878
WO	9409034	AU	51458/93	EP	668875	ZA	9307553
WO	9102547	AU	61790/90	CA	2065362	EP	489061
US	6132719	AU	27892/97	CA	2226968	EP	842949
		JP	9301999	WO	9743315		
EP	347933	DK	3138/89	JP	2112763	PT	90941
		US	5206140				
END OF ANNEX							

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/00827

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos : **1-8, 11, 12, 26-29, 38-40 and 42-50**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The claims are speculative and are not supported by the disclosure, rendering a search across the full scope of the claims economically prohibitive. The search was restricted to deimmunized forms of the 3B6 antibody.

3. Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

(See Supplemental Box)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

The following separate inventions were identified:

1. Claims 9, 10, 13-25, 30-37, 41 and 51 are directed to deimmunized forms of the 3B6 antibody. Deimmunized 3B6 is considered to be the first "special technical feature".
2. Claims 1-7, 42 and 43 are directed to any immunointeractive molecule having specificity for fibrin. The use of molecules that react with fibrin is considered to be the second "special technical feature".
3. Claims 8, 11 and 12 are directed to any deimmunized antibody against the D-dimer fragment of fibrin. The use of deimmunized antibodies specifically directed against the D-dimer fragment of fibrin is the third "special technical feature" identified.
4. Claims 26-29 and 38-40 are directed to any antibody having specificity for blood clots. The use of antibodies to detect blood clots appears to be the fourth "special technical feature".
5. Claims 44-50 are directed to any immunointeractive molecule conjugated to an imaging tag or therapeutic agent. The use of an imaging tag attached to an immunointeractive molecule is considered to be the fifth "special technical feature".

These groups of claims do not relate to a single invention (or to a group of inventions so linked as to form a single general inventive concept), as there is no common "special technical feature" (i.e. no common feature which potentially distinguishes the claims from the prior art). As only Group 1 defines a searchable invention, the search has been restricted to the inventive concept defined in Group 1.